Clozapina (Portuguese Wikipedia)
Analysis of information sources in references of the Wikipedia article "Clozapina" in Portuguese language version.
refsWebsite
Global rank
Portuguese rank
5th place
5th place
1st place
1st place
3,823rd place
5,376th place
low place
3,423rd place
7,927th place
4,251st place
18th place
51st place
low place
low place
3rd place
6th place
low place
low place
4,032nd place
3,054th place
6,512th place
low place
1,735th place
6,685th place
54th place
82nd place
3,011th place
2,540th place
1,523rd place
3,490th place
626th place
441st place
low place
low place
719th place
598th place
low place
low place
bmj.com
- Kuipers E, Yesufu-Udechuku A, Taylor C, Kendall T (fevereiro de 2014). «Management of psychosis and schizophrenia in adults: summary of updated NICE guidance». BMJ. 348: g1173. PMID 24523363. doi:10.1136/bmj.g1173
books.google.com
- Atypical Antipsychotics. [S.l.]: Birkhäuser. 6 de dezembro de 2012. ISBN 9783034884488 – via Google Books
cardiff.ac.uk
orca.cardiff.ac.uk
- Casetta C, Oloyede E, Whiskey E, Taylor DM, Gaughran F, Shergill SS, et al. (setembro de 2020). «A retrospective study of intramuscular clozapine prescription for treatment initiation and maintenance in treatment-resistant psychosis» (PDF). The British Journal of Psychiatry. 217 (3): 506–513. PMID 32605667. doi:10.1192/bjp.2020.115
clozapinerems.com
- «A Guide for Patients and Caregivers: What You Need to Know About Clozapine and Neutropenia» (PDF). Clozapine REMS. Clozapine REMS Program. Consultado em 14 de setembro de 2021. Arquivado do original (PDF) em 22 de dezembro de 2017
consultaremedios.com.br
- consultaremedios.com.br. «Clozapina: menor preço e entrega rápida, compre online | CR». Consulta Remédios. Consultado em 14 de maio de 2023
- consultaremedios.com.br. «Clozapina: menor preço e entrega rápida, compre online | CR». Consulta Remédios. Consultado em 14 de maio de 2023
doi.org
dx.doi.org
- Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, et al. (julho de 2012). «World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance». The World Journal of Biological Psychiatry. 13 (5): 318–378. PMID 22834451. doi:10.3109/15622975.2012.696143
- Buchanan RW, Kreyenbuhl J, Kelly DL, Noel JM, Boggs DL, Fischer BA, et al. (janeiro de 2010). «The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements». Schizophrenia Bulletin. 36 (1): 71–93. PMC 2800144
. PMID 19955390. doi:10.1093/schbul/sbp116 - Gaebel W, Weinmann S, Sartorius N, Rutz W, McIntyre JS (setembro de 2005). «Schizophrenia practice guidelines: international survey and comparison». The British Journal of Psychiatry. 187 (3): 248–255. PMID 16135862. doi:10.1192/bjp.187.3.248
- Kuipers E, Yesufu-Udechuku A, Taylor C, Kendall T (fevereiro de 2014). «Management of psychosis and schizophrenia in adults: summary of updated NICE guidance». BMJ. 348: g1173. PMID 24523363. doi:10.1136/bmj.g1173
- Howes OD, McCutcheon R, Agid O, de Bartolomeis A, van Beveren NJ, Birnbaum ML, et al. (março de 2017). «Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology». The American Journal of Psychiatry. 174 (3): 216–229. PMC 6231547. PMID 27919182. doi:10.1176/appi.ajp.2016.16050503
- Galletly C, Castle D, Dark F, Humberstone V, Jablensky A, Killackey E, et al. (maio de 2016). «Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders». The Australian and New Zealand Journal of Psychiatry. 50 (5): 410–472. PMID 27106681. doi:10.1177/0004867416641195
- Remington G, Addington D, Honer W, Ismail Z, Raedler T, Teehan M (setembro de 2017). «Guidelines for the Pharmacotherapy of Schizophrenia in Adults». Canadian Journal of Psychiatry. 62 (9): 604–616. PMC 5593252. PMID 28703015. doi:10.1177/0706743717720448
- Kane J, Honigfeld G, Singer J, Meltzer H (setembro de 1988). «Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine». Archives of General Psychiatry. 45 (9): 789–796. PMID 3046553. doi:10.1001/archpsyc.1988.01800330013001
- Taipale H, Tanskanen A, Mehtälä J, Vattulainen P, Correll CU, Tiihonen J (fevereiro de 2020). «20-year follow-up study of physical morbidity and mortality in relationship to antipsychotic treatment in a nationwide cohort of 62,250 patients with schizophrenia (FIN20)». World Psychiatry. 19 (1): 61–68. PMC 6953552. PMID 31922669. doi:10.1002/wps.20699
- Masuda T, Misawa F, Takase M, Kane JM, Correll CU (outubro de 2019). «Association With Hospitalization and All-Cause Discontinuation Among Patients With Schizophrenia on Clozapine vs Other Oral Second-Generation Antipsychotics: A Systematic Review and Meta-analysis of Cohort Studies». JAMA Psychiatry. 76 (10): 1052–1062. PMC 6669790. PMID 31365048. doi:10.1001/jamapsychiatry.2019.1702
- «'Last resort' antipsychotic remains the gold standard for treatment-resistant schizophrenia». NIHR Evidence (Plain English summary). 2 de outubro de 2019. doi:10.3310/signal-000826
- Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, et al. (setembro de 2013). «Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis». Lancet. 382 (9896): 951–962. PMID 23810019. doi:10.1016/S0140-6736(13)60733-3
- Taylor D, Shapland L, Laverick G, Bond J, Munro J (dezembro de 2000). «Clozapine – a survey of patient perceptions». Psychiatric Bulletin (em inglês). 24 (12): 450–452. ISSN 0955-6036. doi:10.1192/pb.24.12.450
- Waserman J, Criollo M (maio de 2000). «Subjective experiences of clozapine treatment by patients with chronic schizophrenia». Psychiatric Services. 51 (5): 666–668. PMID 10783189. doi:10.1176/appi.ps.51.5.666
- Vermeulen JM, van Rooijen G, van de Kerkhof MP, Sutterland AL, Correll CU, de Haan L (março de 2019). «Clozapine and Long-Term Mortality Risk in Patients With Schizophrenia: A Systematic Review and Meta-analysis of Studies Lasting 1.1-12.5 Years». Schizophrenia Bulletin. 45 (2): 315–329. PMC 6403051. PMID 29697804. doi:10.1093/schbul/sby052
- Li XH, Zhong XM, Lu L, Zheng W, Wang SB, Rao WW, et al. (março de 2020). «The prevalence of agranulocytosis and related death in clozapine-treated patients: a comprehensive meta-analysis of observational studies». Psychological Medicine. 50 (4): 583–594. PMID 30857568. doi:10.1017/S0033291719000369
- Griffith RW, Saameli K (outubro de 1975). «Letter: Clozapine and agranulocytosis». Lancet. 2 (7936). 657 páginas. PMID 52022. doi:10.1016/S0140-6736(75)90135-X
- Crilly J (março de 2007). «The history of clozapine and its emergence in the US market: a review and analysis». History of Psychiatry. 18 (1): 39–60. PMID 17580753. doi:10.1177/0957154X07070335
- Pardis P, Remington G, Panda R, Lemez M, Agid O (outubro de 2019). «Clozapine and tardive dyskinesia in patients with schizophrenia: A systematic review». Journal of Psychopharmacology. 33 (10): 1187–1198. PMID 31347436. doi:10.1177/0269881119862535
- Hartling L, Abou-Setta AM, Dursun S, Mousavi SS, Pasichnyk D, Newton AS (outubro de 2012). «Antipsychotics in adults with schizophrenia: comparative effectiveness of first-generation versus second-generation medications: a systematic review and meta-analysis». Annals of Internal Medicine. 157 (7): 498–511. PMID 22893011. doi:10.7326/0003-4819-157-7-201210020-00525
- Idänpään-Heikkilä J, Alhava E, Olkinuora M, Palva I (setembro de 1975). «Letter: Clozapine and agranulocytosis». Lancet. 2 (7935). 611 páginas. PMID 51442. doi:10.1016/s0140-6736(75)90206-8
- Amsler HA, Teerenhovi L, Barth E, Harjula K, Vuopio P (outubro de 1977). «Agranulocytosis in patients treated with clozapine. A study of the Finnish epidemic». Acta Psychiatrica Scandinavica. 56 (4): 241–248. PMID 920225. doi:10.1111/j.1600-0447.1977.tb00224.x
- Legge SE, Walters JT (março de 2019). «Genetics of clozapine-associated neutropenia: recent advances, challenges and future perspective». Pharmacogenomics. 20 (4): 279–290. PMC 6563116. PMID 30767710. doi:10.2217/pgs-2018-0188
- de With SA, Pulit SL, Staal WG, Kahn RS, Ophoff RA (julho de 2017). «More than 25 years of genetic studies of clozapine-induced agranulocytosis». The Pharmacogenomics Journal. 17 (4): 304–311. PMID 28418011. doi:10.1038/tpj.2017.6
- The Psychopharmacologists. [S.l.: s.n.] 8 de maio de 2018. ISBN 9780203736159. doi:10.1201/9780203736159
- Sultan RS, Olfson M, Correll CU, Duncan EJ (25 de outubro de 2017). «Evaluating the Effect of the Changes in FDA Guidelines for Clozapine Monitoring». The Journal of Clinical Psychiatry. 78 (8): e933–e939. PMC 5669833. PMID 28742291. doi:10.4088/jcp.16m11152
- Nielsen J, Young C, Ifteni P, Kishimoto T, Xiang YT, Schulte PF, et al. (fevereiro de 2016). «Worldwide Differences in Regulations of Clozapine Use». CNS Drugs. 30 (2): 149–161. PMID 26884144. doi:10.1007/s40263-016-0311-1
- Oloyede E, Casetta C, Dzahini O, Segev A, Gaughran F, Shergill S, et al. (julho de 2021). «There Is Life After the UK Clozapine Central Non-Rechallenge Database». Schizophrenia Bulletin. 47 (4): 1088–1098. PMC 8266568. PMID 33543755. doi:10.1093/schbul/sbab006
- Essali A, Al-Haj Haasan N, Li C, Rathbone J (janeiro de 2009). «Clozapine versus typical neuroleptic medication for schizophrenia». The Cochrane Database of Systematic Reviews. 2009 (1): CD000059. PMC 7065592. PMID 19160174. doi:10.1002/14651858.CD000059.pub2
- Siskind D, McCartney L, Goldschlager R, Kisely S (novembro de 2016). «Clozapine v. first- and second-generation antipsychotics in treatment-refractory schizophrenia: systematic review and meta-analysis». The British Journal of Psychiatry. 209 (5): 385–392. PMID 27388573. doi:10.1192/bjp.bp.115.177261
- Kahn RS, Winter van Rossum I, Leucht S, McGuire P, Lewis SW, Leboyer M, et al. (outubro de 2018). «Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMiSE): a three-phase switching study». The Lancet. Psychiatry. 5 (10): 797–807. PMID 30115598. doi:10.1016/S2215-0366(18)30252-9
- Siskind D, Reddel T, MacCabe JH, Kisely S (junho de 2019). «The impact of clozapine initiation and cessation on psychiatric hospital admissions and bed days: a mirror image cohort study». Psychopharmacology. 236 (6): 1931–1935. PMID 30715572. doi:10.1007/s00213-019-5179-6
- Gaszner P, Makkos Z (maio de 2004). «Clozapine maintenance therapy in schizophrenia». Progress in Neuro-Psychopharmacology & Biological Psychiatry. 28 (3): 465–469. PMID 15093952. doi:10.1016/j.pnpbp.2003.11.011
- Tiihonen J, Lönnqvist J, Wahlbeck K, Klaukka T, Niskanen L, Tanskanen A, Haukka J (agosto de 2009). «11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study)». Lancet. 374 (9690): 620–627. PMID 19595447. doi:10.1016/S0140-6736(09)60742-X
- Taipale H, Lähteenvuo M, Tanskanen A, Mittendorfer-Rutz E, Tiihonen J (janeiro de 2021). «Comparative Effectiveness of Antipsychotics for Risk of Attempted or Completed Suicide Among Persons With Schizophrenia». Schizophrenia Bulletin. 47 (1): 23–30. PMC 7824993. PMID 33428766. doi:10.1093/schbul/sbaa111
- Brown D, Larkin F, Sengupta S, Romero-Ureclay JL, Ross CC, Gupta N, et al. (outubro de 2014). «Clozapine: an effective treatment for seriously violent and psychopathic men with antisocial personality disorder in a UK high-security hospital». CNS Spectrums. 19 (5): 391–402. PMC 4255317. PMID 24698103. doi:10.1017/S1092852914000157
- Krakowski MI, Czobor P, Citrome L, Bark N, Cooper TB (junho de 2006). «Atypical antipsychotic agents in the treatment of violent patients with schizophrenia and schizoaffective disorder». Archives of General Psychiatry. 63 (6): 622–629. PMID 16754835. doi:10.1001/archpsyc.63.6.622
- Dalal B, Larkin E, Leese M, Taylor PJ (junho de 1999). «Clozapine treatment of long-standing schizophrenia and serious violence: a two-year follow-up study of the first 50 patients treated with clozapine in Rampton high security hospital». Criminal Behaviour and Mental Health (em inglês). 9 (2): 168–178. doi:10.1002/cbm.304
- Topiwala A, Fazel S (janeiro de 2011). «The pharmacological management of violence in schizophrenia: a structured review». Expert Review of Neurotherapeutics. 11 (1): 53–63. PMID 21158555. doi:10.1586/ern.10.180
- Frogley C, Taylor D, Dickens G, Picchioni M (outubro de 2012). «A systematic review of the evidence of clozapine's anti-aggressive effects». The International Journal of Neuropsychopharmacology. 15 (9): 1351–1371. PMID 22339930. doi:10.1017/S146114571100201X
- Thomson LD (julho de 2000). «Management of schizophrenia in conditions of high security». Advances in Psychiatric Treatment. 6 (4): 252–260. ISSN 1355-5146. doi:10.1192/apt.6.4.252
- Silva E, Till A, Adshead G (julho de 2017). «Ethical dilemmas in psychiatry: When teams disagree». BJPsych Advances. 23 (4): 231–239. doi:10.1192/apt.bp.116.016147
- Silva E, Higgins M, Hammer B, Stephenson P (junho de 2020). «Clozapine rechallenge and initiation despite neutropenia- a practical, step-by-step guide». BMC Psychiatry. 20 (1). 279 páginas. PMC 7275543. PMID 32503471. doi:10.1186/s12888-020-02592-2
- Till A, Selwood J, Silva E (fevereiro de 2019). «The assertive approach to clozapine: nasogastric administration». BJPsych Bulletin. 43 (1): 21–26. PMC 6327298. PMID 30223913. doi:10.1192/bjb.2018.61
- Fisher WA (janeiro de 2003). «Elements of successful restraint and seclusion reduction programs and their application in a large, urban, state psychiatric hospital». Journal of Psychiatric Practice. 9 (1): 7–15. PMID 15985912. doi:10.1097/00131746-200301000-00003
- Kasinathan J, Mastroianni T (dezembro de 2007). «Evaluating the use of enforced clozapine in an Australian forensic psychiatric setting: two cases». BMC Psychiatry. 7 (S1): P13. ISSN 1471-244X. PMC 3332745. doi:10.1186/1471-244x-7-s1-p13
- Swinton M, Haddock A (janeiro de 2000). «Clozapine in Special Hospital: a retrospective case-control study». The Journal of Forensic Psychiatry. 11 (3): 587–596. ISSN 0958-5184. doi:10.1080/09585180010006205
- Silva E, Higgins M, Hammer B, Stephenson P (1 de janeiro de 2021). «Clozapine re-challenge and initiation following neutropenia: a review and case series of 14 patients in a high-secure forensic hospital». Therapeutic Advances in Psychopharmacology. 11. 20451253211015070 páginas. PMC 8221694. PMID 34221348. doi:10.1177/20451253211015070
- «Schizophrenia, Violence, Clozapine and Risperidone: a Review». British Journal of Psychiatry. 169 (S31): 21–30. Dezembro de 1996. ISSN 0007-1250. doi:10.1192/s0007125000298589
- Swinton M (janeiro de 2001). «Clozapine in severe borderline personality disorder». The Journal of Forensic Psychiatry (em inglês). 12 (3): 580–591. ISSN 0958-5184. doi:10.1080/09585180110091994
- Haw C, Stubbs J (novembro de 2011). «Medication for borderline personality disorder: a survey at a secure hospital». International Journal of Psychiatry in Clinical Practice. 15 (4): 280–285. PMID 22122000. doi:10.3109/13651501.2011.590211
- Henry R, Massey R, Morgan K, Deeks J, Macfarlane H, Holmes N, Silva E (dezembro de 2020). «Evaluation of the effectiveness and acceptability of intramuscular clozapine injection: illustrative case series». BJPsych Bulletin. 44 (6): 239–243. PMC 7684781. PMID 32081110. doi:10.1192/bjb.2020.6
- Casetta C, Oloyede E, Whiskey E, Taylor DM, Gaughran F, Shergill SS, et al. (setembro de 2020). «A retrospective study of intramuscular clozapine prescription for treatment initiation and maintenance in treatment-resistant psychosis» (PDF). The British Journal of Psychiatry. 217 (3): 506–513. PMID 32605667. doi:10.1192/bjp.2020.115
- Lokshin P, Lerner V, Miodownik C, Dobrusin M, Belmaker RH (outubro de 1999). «Parenteral clozapine: five years of experience». Journal of Clinical Psychopharmacology. 19 (5): 479–480. PMID 10505595. doi:10.1097/00004714-199910000-00018
- Schulte PF, Stienen JJ, Bogers J, Cohen D, van Dijk D, Lionarons WH, et al. (novembro de 2007). «Compulsory treatment with clozapine: a retrospective long-term cohort study». International Journal of Law and Psychiatry. 30 (6): 539–545. PMID 17928054. doi:10.1016/j.ijlp.2007.09.003
- McLean G, Juckes L (1 de dezembro de 2001). «Parenteral Clozapine (Clozaril)». Australasian Psychiatry (em inglês). 9 (4). 371 páginas. ISSN 1039-8562. doi:10.1046/j.1440-1665.2001.0367a.x
- Mossman D, Lehrer DS (dezembro de 2000). «Conventional and atypical antipsychotics and the evolving standard of care». Psychiatric Services. 51 (12): 1528–1535. PMID 11097649. doi:10.1176/appi.ps.51.12.1528
- Pompili M, Lester D, Dominici G, Longo L, Marconi G, Forte A, et al. (maio de 2013). «Indications for electroconvulsive treatment in schizophrenia: a systematic review». Schizophrenia Research. 146 (1–3): 1–9. PMID 23499244. doi:10.1016/j.schres.2022.09.021
- Li XB, Tang YL, Wang CY, de Leon J (maio de 2015). «Clozapine for treatment-resistant bipolar disorder: a systematic review». Bipolar Disorders. 17 (3): 235–247. PMID 25346322. doi:10.1111/bdi.12272
- Goodwin GM (junho de 2009). «Evidence-based guidelines for treating bipolar disorder: revised second edition--recommendations from the British Association for Psychopharmacology». Journal of Psychopharmacology. 23 (4): 346–388. PMID 19329543. doi:10.1177/0269881109102919
- Bastiampillai T, Gupta A, Allison S, Chan SK (junho de 2016). «NICE guidance: why not clozapine for treatment-refractory bipolar disorder?». The Lancet. Psychiatry. 3 (6): 502–503. PMID 27262046. doi:10.1016/s2215-0366(16)30081-5
- Yatham LN, Kennedy SH, Parikh SV, Schaffer A, Bond DJ, Frey BN, et al. (março de 2018). «Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder». Bipolar Disorders. 20 (2): 97–170. PMC 5947163. PMID 29536616. doi:10.1111/bdi.12609
- Gartlehner G, Crotty K, Kennedy S, Edlund MJ, Ali R, Siddiqui M, et al. (outubro de 2021). «Pharmacological Treatments for Borderline Personality Disorder: A Systematic Review and Meta-Analysis». CNS Drugs. 35 (10): 1053–1067. PMC 8478737. PMID 34495494. doi:10.26226/morressier.59d4913bd462b8029238a351
- Dickens GL, Frogley C, Mason F, Anagnostakis K, Picchioni MM (7 de outubro de 2016). «Experiences of women in secure care who have been prescribed clozapine for borderline personality disorder». Borderline Personality Disorder and Emotion Dysregulation. 3 (1). 12 páginas. PMC 5055694. PMID 27761261. doi:10.1186/s40479-016-0049-x
- Rohde C, Polcwiartek C, Correll CU, Nielsen J (dezembro de 2018). «Real-World Effectiveness of Clozapine for Borderline Personality Disorder: Results From a 2-Year Mirror-Image Study». Journal of Personality Disorders. 32 (6): 823–837. PMID 29120277. doi:10.1521/pedi_2017_31_328
- Stoffers-Winterling J, Storebø OJ, Lieb K (junho de 2020). «Pharmacotherapy for Borderline Personality Disorder: an Update of Published, Unpublished and Ongoing Studies». Current Psychiatry Reports. 22 (8). 37 páginas. PMC 7275094. PMID 32504127. doi:10.1007/s11920-020-01164-1
- Flanagan RJ, Lally J, Gee S, Lyon R, Every-Palmer S (outubro de 2020). «Clozapine in the treatment of refractory schizophrenia: a practical guide for healthcare professionals». British Medical Bulletin. 135 (1): 73–89. PMC 7585831. PMID 32885238. doi:10.1093/bmb/ldaa024
- Beck K, McCutcheon R, Bloomfield MA, Gaughran F, Reis Marques T, MacCabe J, et al. (dezembro de 2014). «The practical management of refractory schizophrenia--the Maudsley Treatment REview and Assessment Team service approach». Acta Psychiatrica Scandinavica. 130 (6): 427–438. PMID 25201058. doi:10.1111/acps.12327
- Taylor Shubhra Mace Shameem Mir Robert Kerwin D (janeiro de 2000). «A prescription survey of the use of atypical antipsychotics for hospital inpatients in the United Kingdom». International Journal of Psychiatry in Clinical Practice. 4 (1): 41–46. PMID 24927311. doi:10.1080/13651500052048749
- Sharma A (outubro de 2018). «Maintenance doses for clozapine: past and present». BJPsych Bulletin. 42 (5). 217 páginas. PMC 6189983. PMID 30345070. doi:10.1192/bjb.2018.64
- Suzuki T, Remington G, Arenovich T, Uchida H, Agid O, Graff-Guerrero A, Mamo DC (outubro de 2011). «Time course of improvement with antipsychotic medication in treatment-resistant schizophrenia». The British Journal of Psychiatry. 199 (4): 275–280. PMID 22187729. doi:10.1192/bjp.bp.110.083907
- Kapur S, Arenovich T, Agid O, Zipursky R, Lindborg S, Jones B (maio de 2005). «Evidence for onset of antipsychotic effects within the first 24 hours of treatment». The American Journal of Psychiatry. 162 (5): 939–946. PMID 15863796. doi:10.1176/appi.ajp.162.5.939
- «Augmenting Clozapine Response in Treatment-Resistant Schizophreni a». Therapy-Resistant Schizophrenia. Col: Advances in Biological Psychiatry. 26. Basel: KARGER. 2010. pp. 129–151. ISBN 978-3-8055-9511-7. doi:10.1159/000319813
- Schulte P (2003). «What is an adequate trial with clozapine?: therapeutic drug monitoring and time to response in treatment-refractory schizophrenia». Clinical Pharmacokinetics. 42 (7): 607–618. PMID 12844323. doi:10.2165/00003088-200342070-00001
- Conley RR, Carpenter WT, Tamminga CA (setembro de 1997). «Time to clozapine response in a standardized trial». The American Journal of Psychiatry. 154 (9): 1243–1247. PMID 9286183. doi:10.1176/ajp.154.9.1243
- Mistry H, Osborn D (julho de 2011). «Underuse of clozapine in treatment-resistant schizophrenia». Advances in Psychiatric Treatment. 17 (4): 250–255. ISSN 1355-5146. doi:10.1192/apt.bp.110.008128
- Stroup TS, Gerhard T, Crystal S, Huang C, Olfson M (fevereiro de 2014). «Geographic and clinical variation in clozapine use in the United States». Psychiatric Services. 65 (2): 186–192. PMID 24233347. doi:10.1176/appi.ps.201300180
- Downs J, Zinkler M (outubro de 2007). «Clozapine: national review of postcode prescribing». Psychiatric Bulletin (em inglês). 31 (10): 384–387. ISSN 0955-6036. doi:10.1192/pb.bp.106.013144
- Purcell H, Lewis S (novembro de 2000). «Postcode prescribing in psychiatry». Psychiatric Bulletin. 24 (11): 420–422. ISSN 0955-6036. doi:10.1192/pb.24.11.420
- Hayhurst KP, Brown P, Lewis SW (abril de 2003). «Postcode prescribing for schizophrenia». The British Journal of Psychiatry. 182 (4): 281–283. PMID 12668398. doi:10.1192/bjp.182.4.281
- Nielsen J, Røge R, Schjerning O, Sørensen HJ, Taylor D (novembro de 2012). «Geographical and temporal variations in clozapine prescription for schizophrenia». European Neuropsychopharmacology. 22 (11): 818–824. PMID 22503785. doi:10.1016/j.euroneuro.2012.03.003
- Latimer E, Wynant W, Clark R, Malla A, Moodie E, Tamblyn R, Naidu A (abril de 2013). «Underprescribing of clozapine and unexplained variation in use across hospitals and regions in the Canadian province of Québec». Clinical Schizophrenia & Related Psychoses. 7 (1): 33–41. PMID 23367500. doi:10.3371/csrp.lawy.012513
- Whiskey E, Barnard A, Oloyede E, Dzahini O, Taylor DM, Shergill SS (abril de 2021). «An evaluation of the variation and underuse of clozapine in the United Kingdom» (PDF). Acta Psychiatrica Scandinavica. 143 (4): 339–347. PMID 33501659. doi:10.2139/ssrn.3716864
- Kelly DL, Kreyenbuhl J, Dixon L, Love RC, Medoff D, Conley RR (setembro de 2007). «Clozapine underutilization and discontinuation in African Americans due to leucopenia». Schizophrenia Bulletin. 33 (5): 1221–1224. PMC 2632351. PMID 17170061. doi:10.1093/schbul/sbl068
- Mallinger JB, Fisher SG, Brown T, Lamberti JS (janeiro de 2006). «Racial disparities in the use of second-generation antipsychotics for the treatment of schizophrenia». Psychiatric Services. 57 (1): 133–136. PMID 16399976. doi:10.1176/appi.ps.57.1.133
- Copeland LA, Zeber JE, Valenstein M, Blow FC (outubro de 2003). «Racial disparity in the use of atypical antipsychotic medications among veterans». The American Journal of Psychiatry. 160 (10): 1817–1822. PMID 14514496. doi:10.1176/appi.ajp.160.10.1817
- Kelly DL, Dixon LB, Kreyenbuhl JA, Medoff D, Lehman AF, Love RC, et al. (setembro de 2006). «Clozapine utilization and outcomes by race in a public mental health system: 1994-2000». The Journal of Clinical Psychiatry. 67 (9): 1404–1411. PMID 17017827. doi:10.4088/jcp.v67n0911
- Whiskey E, Olofinjana O, Taylor D (junho de 2011). «The importance of the recognition of benign ethnic neutropenia in black patients during treatment with clozapine: case reports and database study». Journal of Psychopharmacology. 25 (6): 842–845. PMID 20305043. doi:10.1177/0269881110364267
- Cirulli G (outubro de 2005). «Clozapine prescribing in adolescent psychiatry: survey of prescribing practice in in-patient units». Psychiatric Bulletin. 29 (10): 377–380. doi:10.1192/pb.29.10.377
- Nielsen J, Dahm M, Lublin H, Taylor D (julho de 2010). «Psychiatrists' attitude towards and knowledge of clozapine treatment». Journal of Psychopharmacology. 24 (7): 965–971. PMID 19164499. doi:10.1177/0269881108100320
- Hodge K, Jespersen S (fevereiro de 2008). «Side-effects and treatment with clozapine: a comparison between the views of consumers and their clinicians». International Journal of Mental Health Nursing. 17 (1): 2–8. PMID 18211398. doi:10.1111/j.1447-0349.2007.00506.x
- Angermeyer MC, Löffler W, Müller P, Schulze B, Priebe S (abril de 2001). «Patients' and relatives' assessment of clozapine treatment». Psychological Medicine. 31 (3): 509–517. PMID 11305859. doi:10.1017/S0033291701003749
- Kelly D, Kreyenbuhl J, Buchanan R, Malhotra A (abril de 2007). «Why Not Clozapine?». Clinical Schizophrenia & Related Psychoses. 1 (1): 92–95. doi:10.3371/csrp.1.1.8
- Downs J, Zinkler M (outubro de 2007). «Clozapine: national review of postcode prescribing». Psychiatric Bulletin. 31 (10): 384–387. ISSN 0955-6036. doi:10.1192/pb.bp.106.013144
- Taylor DM, Young C, Paton C (janeiro de 2003). «Prior antipsychotic prescribing in patients currently receiving clozapine: a case note review». The Journal of Clinical Psychiatry. 64 (1): 30–34. PMID 12590620. doi:10.4088/jcp.v64n0107
- Fayek M, Flowers C, Signorelli D, Simpson G (novembro de 2003). «Psychopharmacology: underuse of evidence-based treatments in psychiatry». Psychiatric Services. 54 (11): 1453–4, 1456. PMID 14600298. doi:10.1176/appi.ps.54.11.1453
- Obermeyer Z, Powers B, Vogeli C, Mullainathan S (outubro de 2019). «Dissecting racial bias in an algorithm used to manage the health of populations». Science. 366 (6464): 447–453. Bibcode:2019Sci...366..447O. PMID 31649194. doi:10.1126/science.aax2342
- Kelly DL, Dixon LB, Kreyenbuhl JA, Medoff D, Lehman AF, Love RC, et al. (setembro de 2006). «Clozapine utilization and outcomes by race in a public mental health system: 1994-2000». The Journal of Clinical Psychiatry. 67 (9): 1404–1411. PMID 17017827. doi:10.4088/JCP.v67n0911
- Atallah-Yunes SA, Ready A, Newburger PE (setembro de 2019). «Benign ethnic neutropenia». Blood Reviews. 37. 100586 páginas. PMC 6702066. PMID 31255364. doi:10.1016/j.blre.2019.06.003
- Haddy TB, Rana SR, Castro O (janeiro de 1999). «Benign ethnic neutropenia: what is a normal absolute neutrophil count?». The Journal of Laboratory and Clinical Medicine. 133 (1): 15–22. PMID 10385477. doi:10.1053/lc.1999.v133.a94931
- Rajagopal S (setembro de 2005). «Clozapine, agranulocytosis, and benign ethnic neutropenia». Postgraduate Medical Journal. 81 (959): 545–546. PMC 1743348. PMID 16143678. doi:10.1136/pgmj.2004.031161
- Reich D, Nalls MA, Kao WH, Akylbekova EL, Tandon A, Patterson N, et al. (janeiro de 2009). «Reduced neutrophil count in people of African descent is due to a regulatory variant in the Duffy antigen receptor for chemokines gene». PLOS Genetics. 5 (1): e1000360. PMC 2628742. PMID 19180233. doi:10.1371/journal.pgen.1000360
- Teodoro T, Nogueira V, Aldeias J, Teles Martins M, Salgado J (setembro de 2022). «Clozapine Associated Periorbital Edema in First Episode Psychosis: A Case Report of a Rare Adverse Effect in Treatment-Resistant Schizophrenia». Journal of Clinical Psychopharmacology. 42 (6): 594–596. PMID 36066404. doi:10.1097/JCP.0000000000001600
- Nielsen J, Correll CU, Manu P, Kane JM (junho de 2013). «Termination of clozapine treatment due to medical reasons: when is it warranted and how can it be avoided?». The Journal of Clinical Psychiatry. 74 (6): 603–13; quiz 613. PMID 23842012. doi:10.4088/JCP.12r08064
- Myles N, Myles H, Xia S, Large M, Kisely S, Galletly C, et al. (agosto de 2018). «Meta-analysis examining the epidemiology of clozapine-associated neutropenia». Acta Psychiatrica Scandinavica. 138 (2): 101–109. PMID 29786829. doi:10.1111/acps.12898
- Whiskey E, Dzahini O, Ramsay R, O'Flynn D, Mijovic A, Gaughran F, et al. (setembro de 2019). «Need to bleed? Clozapine haematological monitoring approaches a time for change». International Clinical Psychopharmacology. 34 (5): 264–268. PMID 30882426. doi:10.1097/yic.0000000000000258
- Kalaria SN, Kelly DL (2019). «Development of point-of-care testing devices to improve clozapine prescribing habits and patient outcomes». Neuropsychiatric Disease and Treatment. 15: 2365–2370. PMC 6708436. PMID 31692521. doi:10.2147/NDT.S216803
- Myles N, Myles H, Clark SR, Bird R, Siskind D (outubro de 2017). «Use of granulocyte-colony stimulating factor to prevent recurrent clozapine-induced neutropenia on drug rechallenge: A systematic review of the literature and clinical recommendations». The Australian and New Zealand Journal of Psychiatry. 51 (10): 980–989. PMID 28747065. doi:10.1177/0004867417720516
- Lally J, Malik S, Krivoy A, Whiskey E, Taylor DM, Gaughran FP, et al. (outubro de 2017). «The Use of Granulocyte Colony-Stimulating Factor in Clozapine Rechallenge: A Systematic Review». Journal of Clinical Psychopharmacology. 37 (5): 600–604. PMID 28817489. doi:10.1097/JCP.0000000000000767
- Siskind D, Sidhu A, Cross J, Chua YT, Myles N, Cohen D, Kisely S (maio de 2020). «Systematic review and meta-analysis of rates of clozapine-associated myocarditis and cardiomyopathy». The Australian and New Zealand Journal of Psychiatry. 54 (5): 467–481. PMID 31957459. doi:10.1177/0004867419898760
- Ronaldson KJ, Fitzgerald PB, Taylor AJ, Topliss DJ, McNeil JJ (junho de 2011). «A new monitoring protocol for clozapine-induced myocarditis based on an analysis of 75 cases and 94 controls». The Australian and New Zealand Journal of Psychiatry. 45 (6): 458–465. PMID 21524186. doi:10.3109/00048674.2011.572852
- Ronaldson KJ, Fitzgerald PB, Taylor AJ, Topliss DJ, Wolfe R, McNeil JJ (novembro de 2012). «Rapid clozapine dose titration and concomitant sodium valproate increase the risk of myocarditis with clozapine: a case-control study». Schizophrenia Research. 141 (2–3): 173–178. PMID 23010488. doi:10.1016/j.schres.2012.08.018
- Segev A, Iqbal E, McDonagh TA, Casetta C, Oloyede E, Piper S, et al. (dezembro de 2021). «Clozapine-induced myocarditis: electronic health register analysis of incidence, timing, clinical markers and diagnostic accuracy». The British Journal of Psychiatry. 219 (6): 644–651. PMC 8636612. PMID 35048875. doi:10.1192/bjp.2021.58
- Griffin JM, Woznica E, Gilotra NA, Nucifora FC (março de 2021). «Clozapine-Associated Myocarditis: A Protocol for Monitoring Upon Clozapine Initiation and Recommendations for How to Conduct a Clozapine Rechallenge». Journal of Clinical Psychopharmacology. 41 (2): 180–185. PMID 33587399. doi:10.1097/JCP.0000000000001358
- Richardson N, Greenway SC, Bousman CA (novembro de 2021). «Clozapine-induced myocarditis and patient outcomes after drug rechallenge following myocarditis: A systematic case review». Psychiatry Research. 305. 114247 páginas. PMID 34715441. doi:10.1101/2021.09.03.21263094
- Palmer SE, McLean RM, Ellis PM, Harrison-Woolrych M (maio de 2008). «Life-threatening clozapine-induced gastrointestinal hypomotility: an analysis of 102 cases». The Journal of Clinical Psychiatry. 69 (5): 759–768. PMID 18452342. doi:10.4088/JCP.v69n0509
- Every-Palmer S, Nowitz M, Stanley J, Grant E, Huthwaite M, Dunn H, Ellis PM (março de 2016). «Clozapine-treated Patients Have Marked Gastrointestinal Hypomotility, the Probable Basis of Life-threatening Gastrointestinal Complications: A Cross Sectional Study». EBioMedicine. 5: 125–134. PMC 4816835. PMID 27077119. doi:10.1016/j.ebiom.2016.02.020
- Cohen D, Bogers JP, van Dijk D, Bakker B, Schulte PF (outubro de 2012). «Beyond white blood cell monitoring: screening in the initial phase of clozapine therapy». The Journal of Clinical Psychiatry. 73 (10): 1307–1312. PMID 23140648. doi:10.4088/JCP.11r06977
- Every-Palmer S, Newton-Howes G, Clarke MJ (janeiro de 2017). «Pharmacological treatment for antipsychotic-related constipation». The Cochrane Database of Systematic Reviews. 1 (1): CD011128. PMC 6465073. PMID 28116777. doi:10.1002/14651858.CD011128.pub2
- Every-Palmer S, Ellis PM, Nowitz M, Stanley J, Grant E, Huthwaite M, Dunn H (janeiro de 2017). «The Porirua Protocol in the Treatment of Clozapine-Induced Gastrointestinal Hypomotility and Constipation: A Pre- and Post-Treatment Study». CNS Drugs. 31 (1): 75–85. PMID 27826741. doi:10.1007/s40263-016-0391-y
- Syed R, Au K, Cahill C, Duggan L, He Y, Udu V, Xia J (julho de 2008). «Pharmacological interventions for clozapine-induced hypersalivation». The Cochrane Database of Systematic Reviews (3): CD005579. PMC 4160791. PMID 18646130. doi:10.1002/14651858.CD005579.pub2
- Segev A, Evans A, Hodsoll J, Whiskey E, Sheriff RS, Shergill S, MacCabe JH (março de 2019). «Hyoscine for clozapine-induced hypersalivation: a double-blind, randomized, placebo-controlled cross-over trial». International Clinical Psychopharmacology. 34 (2): 101–107. PMID 30614850. doi:10.1097/YIC.0000000000000251
- Bird AM, Smith TL, Walton AE (maio de 2011). «Current treatment strategies for clozapine-induced sialorrhea». The Annals of Pharmacotherapy. 45 (5): 667–675. PMID 21540404. doi:10.1345/aph.1P761
- Raja M (julho de 2011). «Clozapine safety, 35 years later». Current Drug Safety. 6 (3): 164–184. PMID 22122392. doi:10.2174/157488611797579230
- Barnes TR, Drake MJ, Paton C (janeiro de 2012). «Nocturnal enuresis with antipsychotic medication». The British Journal of Psychiatry. 200 (1): 7–9. PMID 22215862. doi:10.1192/bjp.bp.111.095737
- Stevenson E, Schembri F, Green DM, Burns JD (agosto de 2013). «Serotonin syndrome associated with clozapine withdrawal». JAMA Neurology. 70 (8): 1054–1055. PMID 23753931. doi:10.1001/jamaneurol.2013.95
- Wadekar M, Syed S (julho de 2010). «Clozapine-withdrawal catatonia». Psychosomatics. 51 (4): 355–355.e2. PMID 20587767. doi:10.1176/appi.psy.51.4.355
- Ahmed S, Chengappa KN, Naidu VR, Baker RW, Parepally H, Schooler NR (setembro de 1998). «Clozapine withdrawal-emergent dystonias and dyskinesias: a case series». The Journal of Clinical Psychiatry. 59 (9): 472–477. PMID 9771818. doi:10.4088/JCP.v59n0906
- Wirshing DA, Wirshing WC, Kysar L, Berisford MA, Goldstein D, Pashdag J, et al. (junho de 1999). «Novel antipsychotics: comparison of weight gain liabilities». The Journal of Clinical Psychiatry. 60 (6): 358–363. PMID 10401912. doi:10.4088/JCP.v60n0602
- Nasrallah HA (janeiro de 2008). «Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles». Molecular Psychiatry. 13 (1): 27–35. PMID 17848919. doi:10.1038/sj.mp.4002066
- Siskind DJ, Leung J, Russell AW, Wysoczanski D, Kisely S (15 de junho de 2016). «Metformin for Clozapine Associated Obesity: A Systematic Review and Meta-Analysis». PLOS ONE. 11 (6): e0156208. Bibcode:2016PLoSO..1156208S. PMC 4909277. PMID 27304831. doi:10.1371/journal.pone.0156208
- De Leon J, Sanz EJ, De Las Cuevas C (janeiro de 2020). «Data From the World Health Organization's Pharmacovigilance Database Supports the Prominent Role of Pneumonia in Mortality Associated With Clozapine Adverse Drug Reactions». Schizophrenia Bulletin. 46 (1): 1–3. PMC 6942151. PMID 31901099. doi:10.1093/schbul/sbz093
- Ponsford M, Castle D, Tahir T, Robinson R, Wade W, Steven R, et al. (setembro de 2018). «Clozapine is associated with secondary antibody deficiency». The British Journal of Psychiatry. 214 (2): 83–89. PMC 6429246. PMID 30259827. doi:10.1192/bjp.2018.152
- Okada M, Fukuyama K, Shiroyama T, Murata M (setembro de 2020). «A Working Hypothesis Regarding Identical Pathomechanisms between Clinical Efficacy and Adverse Reaction of Clozapine via the Activation of Connexin43». International Journal of Molecular Sciences. 21 (19). 7019 páginas. PMC 7583770. PMID 32987640. doi:10.3390/ijms21197019
- Broich K, Heinrich S, Marneros A (julho de 1998). «Acute clozapine overdose: plasma concentration and outcome». Pharmacopsychiatry. 31 (4): 149–151. PMID 9754851. doi:10.1055/s-2007-979318
- Sproule BA, Naranjo CA, Brenmer KE, Hassan PC (dezembro de 1997). «Selective serotonin reuptake inhibitors and CNS drug interactions. A critical review of the evidence». Clinical Pharmacokinetics. 33 (6): 454–471. PMID 9435993. doi:10.2165/00003088-199733060-00004
- Tiihonen J, Vartiainen H, Hakola P (janeiro de 1995). «Carbamazepine-induced changes in plasma levels of neuroleptics». Pharmacopsychiatry. 28 (1): 26–28. PMID 7746842. doi:10.1055/s-2007-979584
- Besag FM, Berry D (2006). «Interactions between antiepileptic and antipsychotic drugs». Drug Safety. 29 (2): 95–118. PMID 16454538. doi:10.2165/00002018-200629020-00001
- Jerling M, Lindström L, Bondesson U, Bertilsson L (agosto de 1994). «Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: evidence from a therapeutic drug monitoring service». Therapeutic Drug Monitoring. 16 (4): 368–374. PMID 7974626. doi:10.1097/00007691-199408000-00006
- Raaska K, Neuvonen PJ (novembro de 2000). «Ciprofloxacin increases serum clozapine and N-desmethylclozapine: a study in patients with schizophrenia». European Journal of Clinical Pharmacology. 56 (8): 585–589. PMID 11151749. doi:10.1007/s002280000192
- Naheed M, Green B (2001). «Focus on clozapine». Current Medical Research and Opinion. 17 (3): 223–229. PMID 11900316. doi:10.1185/0300799039117069
- Wu Y, Blichowski M, Daskalakis ZJ, Wu Z, Liu CC, Cortez MA, Snead OC (setembro de 2011). «Evidence that clozapine directly interacts on the GABAB receptor». NeuroReport. 22 (13): 637–641. PMID 21753741. doi:10.1097/WNR.0b013e328349739b
- Vacher CM, Gassmann M, Desrayaud S, Challet E, Bradaia A, Hoyer D, et al. (maio de 2006). «Hyperdopaminergia and altered locomotor activity in GABAB1-deficient mice». Journal of Neurochemistry. 97 (4): 979–991. PMID 16606363. doi:10.1111/j.1471-4159.2006.03806.x
- Wierońska JM, Kusek M, Tokarski K, Wabno J, Froestl W, Pilc A (julho de 2011). «The GABA B receptor agonist CGP44532 and the positive modulator GS39783 reverse some behavioural changes related to positive syndromes of psychosis in mice». British Journal of Pharmacology. 163 (5): 1034–1047. PMC 3130949. PMID 21371011. doi:10.1111/j.1476-5381.2011.01301.x
- Tanahashi S, Yamamura S, Nakagawa M, Motomura E, Okada M (março de 2012). «Clozapine, but not haloperidol, enhances glial D-serine and L-glutamate release in rat frontal cortex and primary cultured astrocytes». British Journal of Pharmacology. 165 (5): 1543–1555. PMC 3372736. PMID 21880034. doi:10.1111/j.1476-5381.2011.01638.x
- Xi D, Li YC, Snyder MA, Gao RY, Adelman AE, Zhang W, et al. (maio de 2011). «Group II metabotropic glutamate receptor agonist ameliorates MK801-induced dysfunction of NMDA receptors via the Akt/GSK-3β pathway in adult rat prefrontal cortex». Neuropsychopharmacology. 36 (6): 1260–1274. PMC 3079418. PMID 21326193. doi:10.1038/npp.2011.12
- Disanto AR, Golden G (1 de agosto de 2009). «Effect of food on the pharmacokinetics of clozapine orally disintegrating tablet 12.5 mg: a randomized, open-label, crossover study in healthy male subjects». Clinical Drug Investigation. 29 (8): 539–549. PMID 19591515. doi:10.2165/00044011-200929080-00004
- Rostami-Hodjegan A, Amin AM, Spencer EP, Lennard MS, Tucker GT, Flanagan RJ (fevereiro de 2004). «Influence of dose, cigarette smoking, age, sex, and metabolic activity on plasma clozapine concentrations: a predictive model and nomograms to aid clozapine dose adjustment and to assess compliance in individual patients». Journal of Clinical Psychopharmacology. 24 (1): 70–78. PMID 14709950. doi:10.1097/01.jcp.0000106221.36344.4d
- Lane HY, Chang YC, Chang WH, Lin SK, Tseng YT, Jann MW (janeiro de 1999). «Effects of gender and age on plasma levels of clozapine and its metabolites: analyzed by critical statistics». The Journal of Clinical Psychiatry. 60 (1): 36–40. PMID 10074876. doi:10.4088/JCP.v60n0108
- Jin H, Tappenden P, MacCabe JH, Robinson S, Byford S (maio de 2020). «Evaluation of the Cost-effectiveness of Services for Schizophrenia in the UK Across the Entire Care Pathway in a Single Whole-Disease Model». JAMA Network Open. 3 (5): e205888. PMC 7254180. PMID 32459356. doi:10.1001/jamanetworkopen.2020.5888
- Morris S, Hogan T, McGuire A (1998). «The cost-effectiveness of clozapine: a survey of the literature». Clinical Drug Investigation. 15 (2): 137–152. PMID 18370477. doi:10.2165/00044011-199815020-00007
drugs.com
- «Clozapine». The American Society of Health-System Pharmacists. Consultado em 1 de dezembro de 2015. Arquivado do original em 8 de dezembro de 2015
- «Clozapine International Brands». Drugs.com. Consultado em 28 de fevereiro de 2017. Arquivado do original em 1 de março de 2017
ebi.ac.uk
- «clozapine (CHEBI:3766)». www.ebi.ac.uk. Consultado em 1 de outubro de 2021
escholarship.org
- Obermeyer Z, Powers B, Vogeli C, Mullainathan S (outubro de 2019). «Dissecting racial bias in an algorithm used to manage the health of populations». Science. 366 (6464): 447–453. Bibcode:2019Sci...366..447O. PMID 31649194. doi:10.1126/science.aax2342
fda.gov
accessdata.fda.gov
- «Supplemental NDA Approval Letter for Clozaril, NDA 19-758 / S-047» (PDF). United States Food and Drug Administration. 18 de dezembro de 2002. Consultado em 23 de novembro de 2012. Arquivado do original (PDF) em 8 de novembro de 2013
- «Letter to Novartis Pharmaceuticals Corporation» (PDF). Consultado em 20 de setembro de 2009. Arquivado do original (PDF) em 11 de maio de 2011
fda.gov
- «Clozaril, Fazaclo ODT, Versacloz (clozapine): Drug Safety Communication - FDA Strengthens Warning That Untreated Constipation Can Lead to Serious Bowel Problems». FDA. 28 de janeiro de 2020. Consultado em 30 de janeiro de 2020
forbes.com
- «Why Health Care Is Different If You're Black, Latino Or Poor». Forbes (em inglês). Consultado em 16 de setembro de 2021 Verifique o valor de
|display-authors=Pearl R(ajuda)
harvard.edu
ui.adsabs.harvard.edu
- Obermeyer Z, Powers B, Vogeli C, Mullainathan S (outubro de 2019). «Dissecting racial bias in an algorithm used to manage the health of populations». Science. 366 (6464): 447–453. Bibcode:2019Sci...366..447O. PMID 31649194. doi:10.1126/science.aax2342
- Siskind DJ, Leung J, Russell AW, Wysoczanski D, Kisely S (15 de junho de 2016). «Metformin for Clozapine Associated Obesity: A Systematic Review and Meta-Analysis». PLOS ONE. 11 (6): e0156208. Bibcode:2016PLoSO..1156208S. PMC 4909277. PMID 27304831. doi:10.1371/journal.pone.0156208
kcl.ac.uk
kclpure.kcl.ac.uk
- Kahn RS, Winter van Rossum I, Leucht S, McGuire P, Lewis SW, Leboyer M, et al. (outubro de 2018). «Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMiSE): a three-phase switching study». The Lancet. Psychiatry. 5 (10): 797–807. PMID 30115598. doi:10.1016/S2215-0366(18)30252-9
- Siskind D, Reddel T, MacCabe JH, Kisely S (junho de 2019). «The impact of clozapine initiation and cessation on psychiatric hospital admissions and bed days: a mirror image cohort study». Psychopharmacology. 236 (6): 1931–1935. PMID 30715572. doi:10.1007/s00213-019-5179-6
- Whiskey E, Dzahini O, Ramsay R, O'Flynn D, Mijovic A, Gaughran F, et al. (setembro de 2019). «Need to bleed? Clozapine haematological monitoring approaches a time for change». International Clinical Psychopharmacology. 34 (5): 264–268. PMID 30882426. doi:10.1097/yic.0000000000000258
- Lally J, Malik S, Krivoy A, Whiskey E, Taylor DM, Gaughran FP, et al. (outubro de 2017). «The Use of Granulocyte Colony-Stimulating Factor in Clozapine Rechallenge: A Systematic Review». Journal of Clinical Psychopharmacology. 37 (5): 600–604. PMID 28817489. doi:10.1097/JCP.0000000000000767
- Segev A, Evans A, Hodsoll J, Whiskey E, Sheriff RS, Shergill S, MacCabe JH (março de 2019). «Hyoscine for clozapine-induced hypersalivation: a double-blind, randomized, placebo-controlled cross-over trial». International Clinical Psychopharmacology. 34 (2): 101–107. PMID 30614850. doi:10.1097/YIC.0000000000000251
kent.ac.uk
kar.kent.ac.uk
- Whiskey E, Barnard A, Oloyede E, Dzahini O, Taylor DM, Shergill SS (abril de 2021). «An evaluation of the variation and underuse of clozapine in the United Kingdom» (PDF). Acta Psychiatrica Scandinavica. 143 (4): 339–347. PMID 33501659. doi:10.2139/ssrn.3716864
medicalnewstoday.com
- «Racism in healthcare: Statistics and examples». www.medicalnewstoday.com (em inglês). 17 de setembro de 2020. Consultado em 16 de setembro de 2021
medicines.org.uk
- «Clozaril 25 mg Tablets - Summary of Product Characteristics (SmPC)». www.medicines.org.uk. Consultado em 14 de setembro de 2021
- «Clozaril 25 mg Tablets - Summary of Product Characteristics (SmPC) - (emc)». www.medicines.org.uk. Consultado em 15 de setembro de 2021
medscape.com
- «Treatment of Clozapine-Induced Sialorrhea». Consultado em 8 de fevereiro de 2010. Arquivado do original em 9 de fevereiro de 2012
nih.gov
ncbi.nlm.nih.gov
- Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, et al. (julho de 2012). «World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance». The World Journal of Biological Psychiatry. 13 (5): 318–378. PMID 22834451. doi:10.3109/15622975.2012.696143
- Buchanan RW, Kreyenbuhl J, Kelly DL, Noel JM, Boggs DL, Fischer BA, et al. (janeiro de 2010). «The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements». Schizophrenia Bulletin. 36 (1): 71–93. PMC 2800144. PMID 19955390. doi:10.1093/schbul/sbp116
- Gaebel W, Weinmann S, Sartorius N, Rutz W, McIntyre JS (setembro de 2005). «Schizophrenia practice guidelines: international survey and comparison». The British Journal of Psychiatry. 187 (3): 248–255. PMID 16135862. doi:10.1192/bjp.187.3.248
- Kuipers E, Yesufu-Udechuku A, Taylor C, Kendall T (fevereiro de 2014). «Management of psychosis and schizophrenia in adults: summary of updated NICE guidance». BMJ. 348: g1173. PMID 24523363. doi:10.1136/bmj.g1173
- Howes OD, McCutcheon R, Agid O, de Bartolomeis A, van Beveren NJ, Birnbaum ML, et al. (março de 2017). «Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology». The American Journal of Psychiatry. 174 (3): 216–229. PMC 6231547. PMID 27919182. doi:10.1176/appi.ajp.2016.16050503
- Galletly C, Castle D, Dark F, Humberstone V, Jablensky A, Killackey E, et al. (maio de 2016). «Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders». The Australian and New Zealand Journal of Psychiatry. 50 (5): 410–472. PMID 27106681. doi:10.1177/0004867416641195
- Remington G, Addington D, Honer W, Ismail Z, Raedler T, Teehan M (setembro de 2017). «Guidelines for the Pharmacotherapy of Schizophrenia in Adults». Canadian Journal of Psychiatry. 62 (9): 604–616. PMC 5593252. PMID 28703015. doi:10.1177/0706743717720448
- Kane J, Honigfeld G, Singer J, Meltzer H (setembro de 1988). «Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine». Archives of General Psychiatry. 45 (9): 789–796. PMID 3046553. doi:10.1001/archpsyc.1988.01800330013001
- Taipale H, Tanskanen A, Mehtälä J, Vattulainen P, Correll CU, Tiihonen J (fevereiro de 2020). «20-year follow-up study of physical morbidity and mortality in relationship to antipsychotic treatment in a nationwide cohort of 62,250 patients with schizophrenia (FIN20)». World Psychiatry. 19 (1): 61–68. PMC 6953552. PMID 31922669. doi:10.1002/wps.20699
- Masuda T, Misawa F, Takase M, Kane JM, Correll CU (outubro de 2019). «Association With Hospitalization and All-Cause Discontinuation Among Patients With Schizophrenia on Clozapine vs Other Oral Second-Generation Antipsychotics: A Systematic Review and Meta-analysis of Cohort Studies». JAMA Psychiatry. 76 (10): 1052–1062. PMC 6669790. PMID 31365048. doi:10.1001/jamapsychiatry.2019.1702
- Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, et al. (setembro de 2013). «Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis». Lancet. 382 (9896): 951–962. PMID 23810019. doi:10.1016/S0140-6736(13)60733-3
- Waserman J, Criollo M (maio de 2000). «Subjective experiences of clozapine treatment by patients with chronic schizophrenia». Psychiatric Services. 51 (5): 666–668. PMID 10783189. doi:10.1176/appi.ps.51.5.666
- Vermeulen JM, van Rooijen G, van de Kerkhof MP, Sutterland AL, Correll CU, de Haan L (março de 2019). «Clozapine and Long-Term Mortality Risk in Patients With Schizophrenia: A Systematic Review and Meta-analysis of Studies Lasting 1.1-12.5 Years». Schizophrenia Bulletin. 45 (2): 315–329. PMC 6403051. PMID 29697804. doi:10.1093/schbul/sby052
- Li XH, Zhong XM, Lu L, Zheng W, Wang SB, Rao WW, et al. (março de 2020). «The prevalence of agranulocytosis and related death in clozapine-treated patients: a comprehensive meta-analysis of observational studies». Psychological Medicine. 50 (4): 583–594. PMID 30857568. doi:10.1017/S0033291719000369
- Griffith RW, Saameli K (outubro de 1975). «Letter: Clozapine and agranulocytosis». Lancet. 2 (7936). 657 páginas. PMID 52022. doi:10.1016/S0140-6736(75)90135-X
- Crilly J (março de 2007). «The history of clozapine and its emergence in the US market: a review and analysis». History of Psychiatry. 18 (1): 39–60. PMID 17580753. doi:10.1177/0957154X07070335
- Pardis P, Remington G, Panda R, Lemez M, Agid O (outubro de 2019). «Clozapine and tardive dyskinesia in patients with schizophrenia: A systematic review». Journal of Psychopharmacology. 33 (10): 1187–1198. PMID 31347436. doi:10.1177/0269881119862535
- Hartling L, Abou-Setta AM, Dursun S, Mousavi SS, Pasichnyk D, Newton AS (outubro de 2012). «Antipsychotics in adults with schizophrenia: comparative effectiveness of first-generation versus second-generation medications: a systematic review and meta-analysis». Annals of Internal Medicine. 157 (7): 498–511. PMID 22893011. doi:10.7326/0003-4819-157-7-201210020-00525
- Idänpään-Heikkilä J, Alhava E, Olkinuora M, Palva I (setembro de 1975). «Letter: Clozapine and agranulocytosis». Lancet. 2 (7935). 611 páginas. PMID 51442. doi:10.1016/s0140-6736(75)90206-8
- Amsler HA, Teerenhovi L, Barth E, Harjula K, Vuopio P (outubro de 1977). «Agranulocytosis in patients treated with clozapine. A study of the Finnish epidemic». Acta Psychiatrica Scandinavica. 56 (4): 241–248. PMID 920225. doi:10.1111/j.1600-0447.1977.tb00224.x
- Legge SE, Walters JT (março de 2019). «Genetics of clozapine-associated neutropenia: recent advances, challenges and future perspective». Pharmacogenomics. 20 (4): 279–290. PMC 6563116. PMID 30767710. doi:10.2217/pgs-2018-0188
- de With SA, Pulit SL, Staal WG, Kahn RS, Ophoff RA (julho de 2017). «More than 25 years of genetic studies of clozapine-induced agranulocytosis». The Pharmacogenomics Journal. 17 (4): 304–311. PMID 28418011. doi:10.1038/tpj.2017.6
- Sultan RS, Olfson M, Correll CU, Duncan EJ (25 de outubro de 2017). «Evaluating the Effect of the Changes in FDA Guidelines for Clozapine Monitoring». The Journal of Clinical Psychiatry. 78 (8): e933–e939. PMC 5669833. PMID 28742291. doi:10.4088/jcp.16m11152
- Nielsen J, Young C, Ifteni P, Kishimoto T, Xiang YT, Schulte PF, et al. (fevereiro de 2016). «Worldwide Differences in Regulations of Clozapine Use». CNS Drugs. 30 (2): 149–161. PMID 26884144. doi:10.1007/s40263-016-0311-1
- Oloyede E, Casetta C, Dzahini O, Segev A, Gaughran F, Shergill S, et al. (julho de 2021). «There Is Life After the UK Clozapine Central Non-Rechallenge Database». Schizophrenia Bulletin. 47 (4): 1088–1098. PMC 8266568. PMID 33543755. doi:10.1093/schbul/sbab006
- Essali A, Al-Haj Haasan N, Li C, Rathbone J (janeiro de 2009). «Clozapine versus typical neuroleptic medication for schizophrenia». The Cochrane Database of Systematic Reviews. 2009 (1): CD000059. PMC 7065592. PMID 19160174. doi:10.1002/14651858.CD000059.pub2
- Siskind D, McCartney L, Goldschlager R, Kisely S (novembro de 2016). «Clozapine v. first- and second-generation antipsychotics in treatment-refractory schizophrenia: systematic review and meta-analysis». The British Journal of Psychiatry. 209 (5): 385–392. PMID 27388573. doi:10.1192/bjp.bp.115.177261
- Kahn RS, Winter van Rossum I, Leucht S, McGuire P, Lewis SW, Leboyer M, et al. (outubro de 2018). «Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMiSE): a three-phase switching study». The Lancet. Psychiatry. 5 (10): 797–807. PMID 30115598. doi:10.1016/S2215-0366(18)30252-9
- Nyakyoma K, Morriss R (2010). «Effectiveness of clozapine use in delaying hospitalization in routine clinical practice: a 2 year observational study». Psychopharmacology Bulletin. 43 (2): 67–81. PMID 21052043
- Siskind D, Reddel T, MacCabe JH, Kisely S (junho de 2019). «The impact of clozapine initiation and cessation on psychiatric hospital admissions and bed days: a mirror image cohort study». Psychopharmacology. 236 (6): 1931–1935. PMID 30715572. doi:10.1007/s00213-019-5179-6
- Gaszner P, Makkos Z (maio de 2004). «Clozapine maintenance therapy in schizophrenia». Progress in Neuro-Psychopharmacology & Biological Psychiatry. 28 (3): 465–469. PMID 15093952. doi:10.1016/j.pnpbp.2003.11.011
- Tiihonen J, Lönnqvist J, Wahlbeck K, Klaukka T, Niskanen L, Tanskanen A, Haukka J (agosto de 2009). «11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study)». Lancet. 374 (9690): 620–627. PMID 19595447. doi:10.1016/S0140-6736(09)60742-X
- Taipale H, Lähteenvuo M, Tanskanen A, Mittendorfer-Rutz E, Tiihonen J (janeiro de 2021). «Comparative Effectiveness of Antipsychotics for Risk of Attempted or Completed Suicide Among Persons With Schizophrenia». Schizophrenia Bulletin. 47 (1): 23–30. PMC 7824993. PMID 33428766. doi:10.1093/schbul/sbaa111
- Brown D, Larkin F, Sengupta S, Romero-Ureclay JL, Ross CC, Gupta N, et al. (outubro de 2014). «Clozapine: an effective treatment for seriously violent and psychopathic men with antisocial personality disorder in a UK high-security hospital». CNS Spectrums. 19 (5): 391–402. PMC 4255317. PMID 24698103. doi:10.1017/S1092852914000157
- Krakowski MI, Czobor P, Citrome L, Bark N, Cooper TB (junho de 2006). «Atypical antipsychotic agents in the treatment of violent patients with schizophrenia and schizoaffective disorder». Archives of General Psychiatry. 63 (6): 622–629. PMID 16754835. doi:10.1001/archpsyc.63.6.622
- Topiwala A, Fazel S (janeiro de 2011). «The pharmacological management of violence in schizophrenia: a structured review». Expert Review of Neurotherapeutics. 11 (1): 53–63. PMID 21158555. doi:10.1586/ern.10.180
- Frogley C, Taylor D, Dickens G, Picchioni M (outubro de 2012). «A systematic review of the evidence of clozapine's anti-aggressive effects». The International Journal of Neuropsychopharmacology. 15 (9): 1351–1371. PMID 22339930. doi:10.1017/S146114571100201X
- Silva E, Higgins M, Hammer B, Stephenson P (junho de 2020). «Clozapine rechallenge and initiation despite neutropenia- a practical, step-by-step guide». BMC Psychiatry. 20 (1). 279 páginas. PMC 7275543. PMID 32503471. doi:10.1186/s12888-020-02592-2
- Till A, Selwood J, Silva E (fevereiro de 2019). «The assertive approach to clozapine: nasogastric administration». BJPsych Bulletin. 43 (1): 21–26. PMC 6327298. PMID 30223913. doi:10.1192/bjb.2018.61
- Fisher WA (janeiro de 2003). «Elements of successful restraint and seclusion reduction programs and their application in a large, urban, state psychiatric hospital». Journal of Psychiatric Practice. 9 (1): 7–15. PMID 15985912. doi:10.1097/00131746-200301000-00003
- Kasinathan J, Mastroianni T (dezembro de 2007). «Evaluating the use of enforced clozapine in an Australian forensic psychiatric setting: two cases». BMC Psychiatry. 7 (S1): P13. ISSN 1471-244X. PMC 3332745. doi:10.1186/1471-244x-7-s1-p13
- Silva E, Higgins M, Hammer B, Stephenson P (1 de janeiro de 2021). «Clozapine re-challenge and initiation following neutropenia: a review and case series of 14 patients in a high-secure forensic hospital». Therapeutic Advances in Psychopharmacology. 11. 20451253211015070 páginas. PMC 8221694. PMID 34221348. doi:10.1177/20451253211015070
- Haw C, Stubbs J (novembro de 2011). «Medication for borderline personality disorder: a survey at a secure hospital». International Journal of Psychiatry in Clinical Practice. 15 (4): 280–285. PMID 22122000. doi:10.3109/13651501.2011.590211
- Henry R, Massey R, Morgan K, Deeks J, Macfarlane H, Holmes N, Silva E (dezembro de 2020). «Evaluation of the effectiveness and acceptability of intramuscular clozapine injection: illustrative case series». BJPsych Bulletin. 44 (6): 239–243. PMC 7684781. PMID 32081110. doi:10.1192/bjb.2020.6
- Casetta C, Oloyede E, Whiskey E, Taylor DM, Gaughran F, Shergill SS, et al. (setembro de 2020). «A retrospective study of intramuscular clozapine prescription for treatment initiation and maintenance in treatment-resistant psychosis» (PDF). The British Journal of Psychiatry. 217 (3): 506–513. PMID 32605667. doi:10.1192/bjp.2020.115
- Lokshin P, Lerner V, Miodownik C, Dobrusin M, Belmaker RH (outubro de 1999). «Parenteral clozapine: five years of experience». Journal of Clinical Psychopharmacology. 19 (5): 479–480. PMID 10505595. doi:10.1097/00004714-199910000-00018
- Schulte PF, Stienen JJ, Bogers J, Cohen D, van Dijk D, Lionarons WH, et al. (novembro de 2007). «Compulsory treatment with clozapine: a retrospective long-term cohort study». International Journal of Law and Psychiatry. 30 (6): 539–545. PMID 17928054. doi:10.1016/j.ijlp.2007.09.003
- Mossman D, Lehrer DS (dezembro de 2000). «Conventional and atypical antipsychotics and the evolving standard of care». Psychiatric Services. 51 (12): 1528–1535. PMID 11097649. doi:10.1176/appi.ps.51.12.1528
- Pompili M, Lester D, Dominici G, Longo L, Marconi G, Forte A, et al. (maio de 2013). «Indications for electroconvulsive treatment in schizophrenia: a systematic review». Schizophrenia Research. 146 (1–3): 1–9. PMID 23499244. doi:10.1016/j.schres.2022.09.021
- Li XB, Tang YL, Wang CY, de Leon J (maio de 2015). «Clozapine for treatment-resistant bipolar disorder: a systematic review». Bipolar Disorders. 17 (3): 235–247. PMID 25346322. doi:10.1111/bdi.12272
- Goodwin GM (junho de 2009). «Evidence-based guidelines for treating bipolar disorder: revised second edition--recommendations from the British Association for Psychopharmacology». Journal of Psychopharmacology. 23 (4): 346–388. PMID 19329543. doi:10.1177/0269881109102919
- Bastiampillai T, Gupta A, Allison S, Chan SK (junho de 2016). «NICE guidance: why not clozapine for treatment-refractory bipolar disorder?». The Lancet. Psychiatry. 3 (6): 502–503. PMID 27262046. doi:10.1016/s2215-0366(16)30081-5
- Yatham LN, Kennedy SH, Parikh SV, Schaffer A, Bond DJ, Frey BN, et al. (março de 2018). «Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder». Bipolar Disorders. 20 (2): 97–170. PMC 5947163. PMID 29536616. doi:10.1111/bdi.12609
- Gartlehner G, Crotty K, Kennedy S, Edlund MJ, Ali R, Siddiqui M, et al. (outubro de 2021). «Pharmacological Treatments for Borderline Personality Disorder: A Systematic Review and Meta-Analysis». CNS Drugs. 35 (10): 1053–1067. PMC 8478737. PMID 34495494. doi:10.26226/morressier.59d4913bd462b8029238a351
- Beri A, Boydell J (maio de 2014). «Clozapine in borderline personality disorder: a review of the evidence». Annals of Clinical Psychiatry. 26 (2): 139–144. PMID 24812651
- Frogley C, Anagnostakis K, Mitchell S, Mason F, Taylor D, Dickens G, Picchioni MM (maio de 2013). «A case series of clozapine for borderline personality disorder». Annals of Clinical Psychiatry. 25 (2): 125–134. PMID 23638443
- Dickens GL, Frogley C, Mason F, Anagnostakis K, Picchioni MM (7 de outubro de 2016). «Experiences of women in secure care who have been prescribed clozapine for borderline personality disorder». Borderline Personality Disorder and Emotion Dysregulation. 3 (1). 12 páginas. PMC 5055694. PMID 27761261. doi:10.1186/s40479-016-0049-x
- Rohde C, Polcwiartek C, Correll CU, Nielsen J (dezembro de 2018). «Real-World Effectiveness of Clozapine for Borderline Personality Disorder: Results From a 2-Year Mirror-Image Study». Journal of Personality Disorders. 32 (6): 823–837. PMID 29120277. doi:10.1521/pedi_2017_31_328
- Stoffers-Winterling J, Storebø OJ, Lieb K (junho de 2020). «Pharmacotherapy for Borderline Personality Disorder: an Update of Published, Unpublished and Ongoing Studies». Current Psychiatry Reports. 22 (8). 37 páginas. PMC 7275094. PMID 32504127. doi:10.1007/s11920-020-01164-1
- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4857858/
- Flanagan RJ, Lally J, Gee S, Lyon R, Every-Palmer S (outubro de 2020). «Clozapine in the treatment of refractory schizophrenia: a practical guide for healthcare professionals». British Medical Bulletin. 135 (1): 73–89. PMC 7585831. PMID 32885238. doi:10.1093/bmb/ldaa024
- Beck K, McCutcheon R, Bloomfield MA, Gaughran F, Reis Marques T, MacCabe J, et al. (dezembro de 2014). «The practical management of refractory schizophrenia--the Maudsley Treatment REview and Assessment Team service approach». Acta Psychiatrica Scandinavica. 130 (6): 427–438. PMID 25201058. doi:10.1111/acps.12327
- Taylor Shubhra Mace Shameem Mir Robert Kerwin D (janeiro de 2000). «A prescription survey of the use of atypical antipsychotics for hospital inpatients in the United Kingdom». International Journal of Psychiatry in Clinical Practice. 4 (1): 41–46. PMID 24927311. doi:10.1080/13651500052048749
- Sharma A (outubro de 2018). «Maintenance doses for clozapine: past and present». BJPsych Bulletin. 42 (5). 217 páginas. PMC 6189983. PMID 30345070. doi:10.1192/bjb.2018.64
- Suzuki T, Remington G, Arenovich T, Uchida H, Agid O, Graff-Guerrero A, Mamo DC (outubro de 2011). «Time course of improvement with antipsychotic medication in treatment-resistant schizophrenia». The British Journal of Psychiatry. 199 (4): 275–280. PMID 22187729. doi:10.1192/bjp.bp.110.083907
- Kapur S, Arenovich T, Agid O, Zipursky R, Lindborg S, Jones B (maio de 2005). «Evidence for onset of antipsychotic effects within the first 24 hours of treatment». The American Journal of Psychiatry. 162 (5): 939–946. PMID 15863796. doi:10.1176/appi.ajp.162.5.939
- Schulte P (2003). «What is an adequate trial with clozapine?: therapeutic drug monitoring and time to response in treatment-refractory schizophrenia». Clinical Pharmacokinetics. 42 (7): 607–618. PMID 12844323. doi:10.2165/00003088-200342070-00001
- Conley RR, Carpenter WT, Tamminga CA (setembro de 1997). «Time to clozapine response in a standardized trial». The American Journal of Psychiatry. 154 (9): 1243–1247. PMID 9286183. doi:10.1176/ajp.154.9.1243
- Stroup TS, Gerhard T, Crystal S, Huang C, Olfson M (fevereiro de 2014). «Geographic and clinical variation in clozapine use in the United States». Psychiatric Services. 65 (2): 186–192. PMID 24233347. doi:10.1176/appi.ps.201300180
- Hayhurst KP, Brown P, Lewis SW (abril de 2003). «Postcode prescribing for schizophrenia». The British Journal of Psychiatry. 182 (4): 281–283. PMID 12668398. doi:10.1192/bjp.182.4.281
- Nielsen J, Røge R, Schjerning O, Sørensen HJ, Taylor D (novembro de 2012). «Geographical and temporal variations in clozapine prescription for schizophrenia». European Neuropsychopharmacology. 22 (11): 818–824. PMID 22503785. doi:10.1016/j.euroneuro.2012.03.003
- Latimer E, Wynant W, Clark R, Malla A, Moodie E, Tamblyn R, Naidu A (abril de 2013). «Underprescribing of clozapine and unexplained variation in use across hospitals and regions in the Canadian province of Québec». Clinical Schizophrenia & Related Psychoses. 7 (1): 33–41. PMID 23367500. doi:10.3371/csrp.lawy.012513
- Whiskey E, Barnard A, Oloyede E, Dzahini O, Taylor DM, Shergill SS (abril de 2021). «An evaluation of the variation and underuse of clozapine in the United Kingdom» (PDF). Acta Psychiatrica Scandinavica. 143 (4): 339–347. PMID 33501659. doi:10.2139/ssrn.3716864
- Kelly DL, Kreyenbuhl J, Dixon L, Love RC, Medoff D, Conley RR (setembro de 2007). «Clozapine underutilization and discontinuation in African Americans due to leucopenia». Schizophrenia Bulletin. 33 (5): 1221–1224. PMC 2632351. PMID 17170061. doi:10.1093/schbul/sbl068
- Mallinger JB, Fisher SG, Brown T, Lamberti JS (janeiro de 2006). «Racial disparities in the use of second-generation antipsychotics for the treatment of schizophrenia». Psychiatric Services. 57 (1): 133–136. PMID 16399976. doi:10.1176/appi.ps.57.1.133
- Copeland LA, Zeber JE, Valenstein M, Blow FC (outubro de 2003). «Racial disparity in the use of atypical antipsychotic medications among veterans». The American Journal of Psychiatry. 160 (10): 1817–1822. PMID 14514496. doi:10.1176/appi.ajp.160.10.1817
- Kelly DL, Dixon LB, Kreyenbuhl JA, Medoff D, Lehman AF, Love RC, et al. (setembro de 2006). «Clozapine utilization and outcomes by race in a public mental health system: 1994-2000». The Journal of Clinical Psychiatry. 67 (9): 1404–1411. PMID 17017827. doi:10.4088/jcp.v67n0911
- Whiskey E, Olofinjana O, Taylor D (junho de 2011). «The importance of the recognition of benign ethnic neutropenia in black patients during treatment with clozapine: case reports and database study». Journal of Psychopharmacology. 25 (6): 842–845. PMID 20305043. doi:10.1177/0269881110364267
- Nielsen J, Dahm M, Lublin H, Taylor D (julho de 2010). «Psychiatrists' attitude towards and knowledge of clozapine treatment». Journal of Psychopharmacology. 24 (7): 965–971. PMID 19164499. doi:10.1177/0269881108100320
- Hodge K, Jespersen S (fevereiro de 2008). «Side-effects and treatment with clozapine: a comparison between the views of consumers and their clinicians». International Journal of Mental Health Nursing. 17 (1): 2–8. PMID 18211398. doi:10.1111/j.1447-0349.2007.00506.x
- Angermeyer MC, Löffler W, Müller P, Schulze B, Priebe S (abril de 2001). «Patients' and relatives' assessment of clozapine treatment». Psychological Medicine. 31 (3): 509–517. PMID 11305859. doi:10.1017/S0033291701003749
- Taylor DM, Young C, Paton C (janeiro de 2003). «Prior antipsychotic prescribing in patients currently receiving clozapine: a case note review». The Journal of Clinical Psychiatry. 64 (1): 30–34. PMID 12590620. doi:10.4088/jcp.v64n0107
- Fayek M, Flowers C, Signorelli D, Simpson G (novembro de 2003). «Psychopharmacology: underuse of evidence-based treatments in psychiatry». Psychiatric Services. 54 (11): 1453–4, 1456. PMID 14600298. doi:10.1176/appi.ps.54.11.1453
- Stress (em inglês). [S.l.]: National Academies Press (US). 2004
- Obermeyer Z, Powers B, Vogeli C, Mullainathan S (outubro de 2019). «Dissecting racial bias in an algorithm used to manage the health of populations». Science. 366 (6464): 447–453. Bibcode:2019Sci...366..447O. PMID 31649194. doi:10.1126/science.aax2342
- Kelly DL, Dixon LB, Kreyenbuhl JA, Medoff D, Lehman AF, Love RC, et al. (setembro de 2006). «Clozapine utilization and outcomes by race in a public mental health system: 1994-2000». The Journal of Clinical Psychiatry. 67 (9): 1404–1411. PMID 17017827. doi:10.4088/JCP.v67n0911
- Atallah-Yunes SA, Ready A, Newburger PE (setembro de 2019). «Benign ethnic neutropenia». Blood Reviews. 37. 100586 páginas. PMC 6702066. PMID 31255364. doi:10.1016/j.blre.2019.06.003
- Haddy TB, Rana SR, Castro O (janeiro de 1999). «Benign ethnic neutropenia: what is a normal absolute neutrophil count?». The Journal of Laboratory and Clinical Medicine. 133 (1): 15–22. PMID 10385477. doi:10.1053/lc.1999.v133.a94931
- Rajagopal S (setembro de 2005). «Clozapine, agranulocytosis, and benign ethnic neutropenia». Postgraduate Medical Journal. 81 (959): 545–546. PMC 1743348. PMID 16143678. doi:10.1136/pgmj.2004.031161
- Reich D, Nalls MA, Kao WH, Akylbekova EL, Tandon A, Patterson N, et al. (janeiro de 2009). «Reduced neutrophil count in people of African descent is due to a regulatory variant in the Duffy antigen receptor for chemokines gene». PLOS Genetics. 5 (1): e1000360. PMC 2628742. PMID 19180233. doi:10.1371/journal.pgen.1000360
- Teodoro T, Nogueira V, Aldeias J, Teles Martins M, Salgado J (setembro de 2022). «Clozapine Associated Periorbital Edema in First Episode Psychosis: A Case Report of a Rare Adverse Effect in Treatment-Resistant Schizophrenia». Journal of Clinical Psychopharmacology. 42 (6): 594–596. PMID 36066404. doi:10.1097/JCP.0000000000001600
- Nielsen J, Correll CU, Manu P, Kane JM (junho de 2013). «Termination of clozapine treatment due to medical reasons: when is it warranted and how can it be avoided?». The Journal of Clinical Psychiatry. 74 (6): 603–13; quiz 613. PMID 23842012. doi:10.4088/JCP.12r08064
- Myles N, Myles H, Xia S, Large M, Kisely S, Galletly C, et al. (agosto de 2018). «Meta-analysis examining the epidemiology of clozapine-associated neutropenia». Acta Psychiatrica Scandinavica. 138 (2): 101–109. PMID 29786829. doi:10.1111/acps.12898
- Whiskey E, Dzahini O, Ramsay R, O'Flynn D, Mijovic A, Gaughran F, et al. (setembro de 2019). «Need to bleed? Clozapine haematological monitoring approaches a time for change». International Clinical Psychopharmacology. 34 (5): 264–268. PMID 30882426. doi:10.1097/yic.0000000000000258
- Kalaria SN, Kelly DL (2019). «Development of point-of-care testing devices to improve clozapine prescribing habits and patient outcomes». Neuropsychiatric Disease and Treatment. 15: 2365–2370. PMC 6708436. PMID 31692521. doi:10.2147/NDT.S216803
- Myles N, Myles H, Clark SR, Bird R, Siskind D (outubro de 2017). «Use of granulocyte-colony stimulating factor to prevent recurrent clozapine-induced neutropenia on drug rechallenge: A systematic review of the literature and clinical recommendations». The Australian and New Zealand Journal of Psychiatry. 51 (10): 980–989. PMID 28747065. doi:10.1177/0004867417720516
- Lally J, Malik S, Krivoy A, Whiskey E, Taylor DM, Gaughran FP, et al. (outubro de 2017). «The Use of Granulocyte Colony-Stimulating Factor in Clozapine Rechallenge: A Systematic Review». Journal of Clinical Psychopharmacology. 37 (5): 600–604. PMID 28817489. doi:10.1097/JCP.0000000000000767
- Siskind D, Sidhu A, Cross J, Chua YT, Myles N, Cohen D, Kisely S (maio de 2020). «Systematic review and meta-analysis of rates of clozapine-associated myocarditis and cardiomyopathy». The Australian and New Zealand Journal of Psychiatry. 54 (5): 467–481. PMID 31957459. doi:10.1177/0004867419898760
- Ronaldson KJ, Fitzgerald PB, Taylor AJ, Topliss DJ, McNeil JJ (junho de 2011). «A new monitoring protocol for clozapine-induced myocarditis based on an analysis of 75 cases and 94 controls». The Australian and New Zealand Journal of Psychiatry. 45 (6): 458–465. PMID 21524186. doi:10.3109/00048674.2011.572852
- Ronaldson KJ, Fitzgerald PB, Taylor AJ, Topliss DJ, Wolfe R, McNeil JJ (novembro de 2012). «Rapid clozapine dose titration and concomitant sodium valproate increase the risk of myocarditis with clozapine: a case-control study». Schizophrenia Research. 141 (2–3): 173–178. PMID 23010488. doi:10.1016/j.schres.2012.08.018
- Segev A, Iqbal E, McDonagh TA, Casetta C, Oloyede E, Piper S, et al. (dezembro de 2021). «Clozapine-induced myocarditis: electronic health register analysis of incidence, timing, clinical markers and diagnostic accuracy». The British Journal of Psychiatry. 219 (6): 644–651. PMC 8636612. PMID 35048875. doi:10.1192/bjp.2021.58
- Griffin JM, Woznica E, Gilotra NA, Nucifora FC (março de 2021). «Clozapine-Associated Myocarditis: A Protocol for Monitoring Upon Clozapine Initiation and Recommendations for How to Conduct a Clozapine Rechallenge». Journal of Clinical Psychopharmacology. 41 (2): 180–185. PMID 33587399. doi:10.1097/JCP.0000000000001358
- Richardson N, Greenway SC, Bousman CA (novembro de 2021). «Clozapine-induced myocarditis and patient outcomes after drug rechallenge following myocarditis: A systematic case review». Psychiatry Research. 305. 114247 páginas. PMID 34715441. doi:10.1101/2021.09.03.21263094
- Palmer SE, McLean RM, Ellis PM, Harrison-Woolrych M (maio de 2008). «Life-threatening clozapine-induced gastrointestinal hypomotility: an analysis of 102 cases». The Journal of Clinical Psychiatry. 69 (5): 759–768. PMID 18452342. doi:10.4088/JCP.v69n0509
- Every-Palmer S, Nowitz M, Stanley J, Grant E, Huthwaite M, Dunn H, Ellis PM (março de 2016). «Clozapine-treated Patients Have Marked Gastrointestinal Hypomotility, the Probable Basis of Life-threatening Gastrointestinal Complications: A Cross Sectional Study». EBioMedicine. 5: 125–134. PMC 4816835. PMID 27077119. doi:10.1016/j.ebiom.2016.02.020
- Cohen D, Bogers JP, van Dijk D, Bakker B, Schulte PF (outubro de 2012). «Beyond white blood cell monitoring: screening in the initial phase of clozapine therapy». The Journal of Clinical Psychiatry. 73 (10): 1307–1312. PMID 23140648. doi:10.4088/JCP.11r06977
- Every-Palmer S, Newton-Howes G, Clarke MJ (janeiro de 2017). «Pharmacological treatment for antipsychotic-related constipation». The Cochrane Database of Systematic Reviews. 1 (1): CD011128. PMC 6465073. PMID 28116777. doi:10.1002/14651858.CD011128.pub2
- Every-Palmer S, Ellis PM, Nowitz M, Stanley J, Grant E, Huthwaite M, Dunn H (janeiro de 2017). «The Porirua Protocol in the Treatment of Clozapine-Induced Gastrointestinal Hypomotility and Constipation: A Pre- and Post-Treatment Study». CNS Drugs. 31 (1): 75–85. PMID 27826741. doi:10.1007/s40263-016-0391-y
- Syed R, Au K, Cahill C, Duggan L, He Y, Udu V, Xia J (julho de 2008). «Pharmacological interventions for clozapine-induced hypersalivation». The Cochrane Database of Systematic Reviews (3): CD005579. PMC 4160791. PMID 18646130. doi:10.1002/14651858.CD005579.pub2
- Segev A, Evans A, Hodsoll J, Whiskey E, Sheriff RS, Shergill S, MacCabe JH (março de 2019). «Hyoscine for clozapine-induced hypersalivation: a double-blind, randomized, placebo-controlled cross-over trial». International Clinical Psychopharmacology. 34 (2): 101–107. PMID 30614850. doi:10.1097/YIC.0000000000000251
- Bird AM, Smith TL, Walton AE (maio de 2011). «Current treatment strategies for clozapine-induced sialorrhea». The Annals of Pharmacotherapy. 45 (5): 667–675. PMID 21540404. doi:10.1345/aph.1P761
- Raja M (julho de 2011). «Clozapine safety, 35 years later». Current Drug Safety. 6 (3): 164–184. PMID 22122392. doi:10.2174/157488611797579230
- Barnes TR, Drake MJ, Paton C (janeiro de 2012). «Nocturnal enuresis with antipsychotic medication». The British Journal of Psychiatry. 200 (1): 7–9. PMID 22215862. doi:10.1192/bjp.bp.111.095737
- Stevenson E, Schembri F, Green DM, Burns JD (agosto de 2013). «Serotonin syndrome associated with clozapine withdrawal». JAMA Neurology. 70 (8): 1054–1055. PMID 23753931. doi:10.1001/jamaneurol.2013.95
- Wadekar M, Syed S (julho de 2010). «Clozapine-withdrawal catatonia». Psychosomatics. 51 (4): 355–355.e2. PMID 20587767. doi:10.1176/appi.psy.51.4.355
- Ahmed S, Chengappa KN, Naidu VR, Baker RW, Parepally H, Schooler NR (setembro de 1998). «Clozapine withdrawal-emergent dystonias and dyskinesias: a case series». The Journal of Clinical Psychiatry. 59 (9): 472–477. PMID 9771818. doi:10.4088/JCP.v59n0906
- Szafrański T, Gmurkowski K (1999). «[Clozapine withdrawal. A review]». Psychiatria Polska. 33 (1): 51–67. PMID 10786215
- Wirshing DA, Wirshing WC, Kysar L, Berisford MA, Goldstein D, Pashdag J, et al. (junho de 1999). «Novel antipsychotics: comparison of weight gain liabilities». The Journal of Clinical Psychiatry. 60 (6): 358–363. PMID 10401912. doi:10.4088/JCP.v60n0602
- Nasrallah HA (janeiro de 2008). «Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles». Molecular Psychiatry. 13 (1): 27–35. PMID 17848919. doi:10.1038/sj.mp.4002066
- Siskind DJ, Leung J, Russell AW, Wysoczanski D, Kisely S (15 de junho de 2016). «Metformin for Clozapine Associated Obesity: A Systematic Review and Meta-Analysis». PLOS ONE. 11 (6): e0156208. Bibcode:2016PLoSO..1156208S. PMC 4909277. PMID 27304831. doi:10.1371/journal.pone.0156208
- De Leon J, Sanz EJ, De Las Cuevas C (janeiro de 2020). «Data From the World Health Organization's Pharmacovigilance Database Supports the Prominent Role of Pneumonia in Mortality Associated With Clozapine Adverse Drug Reactions». Schizophrenia Bulletin. 46 (1): 1–3. PMC 6942151. PMID 31901099. doi:10.1093/schbul/sbz093
- Ponsford M, Castle D, Tahir T, Robinson R, Wade W, Steven R, et al. (setembro de 2018). «Clozapine is associated with secondary antibody deficiency». The British Journal of Psychiatry. 214 (2): 83–89. PMC 6429246. PMID 30259827. doi:10.1192/bjp.2018.152
- Okada M, Fukuyama K, Shiroyama T, Murata M (setembro de 2020). «A Working Hypothesis Regarding Identical Pathomechanisms between Clinical Efficacy and Adverse Reaction of Clozapine via the Activation of Connexin43». International Journal of Molecular Sciences. 21 (19). 7019 páginas. PMC 7583770. PMID 32987640. doi:10.3390/ijms21197019
- Keck PE, McElroy SL (2002). «Clinical pharmacodynamics and pharmacokinetics of antimanic and mood-stabilizing medications». The Journal of Clinical Psychiatry. 63 (Suppl 4): 3–11. PMID 11913673
- Broich K, Heinrich S, Marneros A (julho de 1998). «Acute clozapine overdose: plasma concentration and outcome». Pharmacopsychiatry. 31 (4): 149–151. PMID 9754851. doi:10.1055/s-2007-979318
- Sproule BA, Naranjo CA, Brenmer KE, Hassan PC (dezembro de 1997). «Selective serotonin reuptake inhibitors and CNS drug interactions. A critical review of the evidence». Clinical Pharmacokinetics. 33 (6): 454–471. PMID 9435993. doi:10.2165/00003088-199733060-00004
- Tiihonen J, Vartiainen H, Hakola P (janeiro de 1995). «Carbamazepine-induced changes in plasma levels of neuroleptics». Pharmacopsychiatry. 28 (1): 26–28. PMID 7746842. doi:10.1055/s-2007-979584
- Besag FM, Berry D (2006). «Interactions between antiepileptic and antipsychotic drugs». Drug Safety. 29 (2): 95–118. PMID 16454538. doi:10.2165/00002018-200629020-00001
- Jerling M, Lindström L, Bondesson U, Bertilsson L (agosto de 1994). «Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: evidence from a therapeutic drug monitoring service». Therapeutic Drug Monitoring. 16 (4): 368–374. PMID 7974626. doi:10.1097/00007691-199408000-00006
- Raaska K, Neuvonen PJ (novembro de 2000). «Ciprofloxacin increases serum clozapine and N-desmethylclozapine: a study in patients with schizophrenia». European Journal of Clinical Pharmacology. 56 (8): 585–589. PMID 11151749. doi:10.1007/s002280000192
- Naheed M, Green B (2001). «Focus on clozapine». Current Medical Research and Opinion. 17 (3): 223–229. PMID 11900316. doi:10.1185/0300799039117069
- Wu Y, Blichowski M, Daskalakis ZJ, Wu Z, Liu CC, Cortez MA, Snead OC (setembro de 2011). «Evidence that clozapine directly interacts on the GABAB receptor». NeuroReport. 22 (13): 637–641. PMID 21753741. doi:10.1097/WNR.0b013e328349739b
- Vacher CM, Gassmann M, Desrayaud S, Challet E, Bradaia A, Hoyer D, et al. (maio de 2006). «Hyperdopaminergia and altered locomotor activity in GABAB1-deficient mice». Journal of Neurochemistry. 97 (4): 979–991. PMID 16606363. doi:10.1111/j.1471-4159.2006.03806.x
- Wierońska JM, Kusek M, Tokarski K, Wabno J, Froestl W, Pilc A (julho de 2011). «The GABA B receptor agonist CGP44532 and the positive modulator GS39783 reverse some behavioural changes related to positive syndromes of psychosis in mice». British Journal of Pharmacology. 163 (5): 1034–1047. PMC 3130949. PMID 21371011. doi:10.1111/j.1476-5381.2011.01301.x
- Tanahashi S, Yamamura S, Nakagawa M, Motomura E, Okada M (março de 2012). «Clozapine, but not haloperidol, enhances glial D-serine and L-glutamate release in rat frontal cortex and primary cultured astrocytes». British Journal of Pharmacology. 165 (5): 1543–1555. PMC 3372736. PMID 21880034. doi:10.1111/j.1476-5381.2011.01638.x
- Xi D, Li YC, Snyder MA, Gao RY, Adelman AE, Zhang W, et al. (maio de 2011). «Group II metabotropic glutamate receptor agonist ameliorates MK801-induced dysfunction of NMDA receptors via the Akt/GSK-3β pathway in adult rat prefrontal cortex». Neuropsychopharmacology. 36 (6): 1260–1274. PMC 3079418. PMID 21326193. doi:10.1038/npp.2011.12
- Disanto AR, Golden G (1 de agosto de 2009). «Effect of food on the pharmacokinetics of clozapine orally disintegrating tablet 12.5 mg: a randomized, open-label, crossover study in healthy male subjects». Clinical Drug Investigation. 29 (8): 539–549. PMID 19591515. doi:10.2165/00044011-200929080-00004
- Rostami-Hodjegan A, Amin AM, Spencer EP, Lennard MS, Tucker GT, Flanagan RJ (fevereiro de 2004). «Influence of dose, cigarette smoking, age, sex, and metabolic activity on plasma clozapine concentrations: a predictive model and nomograms to aid clozapine dose adjustment and to assess compliance in individual patients». Journal of Clinical Psychopharmacology. 24 (1): 70–78. PMID 14709950. doi:10.1097/01.jcp.0000106221.36344.4d
- Lane HY, Chang YC, Chang WH, Lin SK, Tseng YT, Jann MW (janeiro de 1999). «Effects of gender and age on plasma levels of clozapine and its metabolites: analyzed by critical statistics». The Journal of Clinical Psychiatry. 60 (1): 36–40. PMID 10074876. doi:10.4088/JCP.v60n0108
- Oh PI, Iskedjian M, Addis A, Lanctôt K, Einarson TR (2001). «Pharmacoeconomic evaluation of clozapine in treatment-resistant schizophrenia: a cost-utility analysis». The Canadian Journal of Clinical Pharmacology. 8 (4): 199–206. PMID 11743592
- Jin H, Tappenden P, MacCabe JH, Robinson S, Byford S (maio de 2020). «Evaluation of the Cost-effectiveness of Services for Schizophrenia in the UK Across the Entire Care Pathway in a Single Whole-Disease Model». JAMA Network Open. 3 (5): e205888. PMC 7254180. PMID 32459356. doi:10.1001/jamanetworkopen.2020.5888
- Morris S, Hogan T, McGuire A (1998). «The cost-effectiveness of clozapine: a survey of the literature». Clinical Drug Investigation. 15 (2): 137–152. PMID 18370477. doi:10.2165/00044011-199815020-00007
pubchem.ncbi.nlm.nih.gov
- «Clozapine | C18H19ClN4». PubChem. U.S. Library of Medicine. Consultado em 16 de julho de 2017. Arquivado do original em 24 de dezembro de 2013
nihr.ac.uk
evidence.nihr.ac.uk
- «'Last resort' antipsychotic remains the gold standard for treatment-resistant schizophrenia». NIHR Evidence (Plain English summary). 2 de outubro de 2019. doi:10.3310/signal-000826
fundingawards.nihr.ac.uk
- «NIHR Funding and Awards Search Website». fundingawards.nihr.ac.uk. Consultado em 14 de setembro de 2021
primarypsychiatry.com
- Robinson DS (2007). «CNS Receptor Partial Agonists: A New Approach to Drug Discovery». Primary Psychiatry. 14 (8): 22–24. Cópia arquivada em 18 de janeiro de 2012
psychiatryonline.org
ps.psychiatryonline.org
qmul.ac.uk
qmro.qmul.ac.uk
- Angermeyer MC, Löffler W, Müller P, Schulze B, Priebe S (abril de 2001). «Patients' and relatives' assessment of clozapine treatment». Psychological Medicine. 31 (3): 509–517. PMID 11305859. doi:10.1017/S0033291701003749
raps.org
- «FDA Modifies REMS Program for Clozapine». www.raps.org. Consultado em 14 de agosto de 2021
rxlist.com
- Novartis Pharmaceuticals (abril de 2006). «Prescribing Information». Novartis Pharmaceuticals. 36 páginas. Consultado em 29 de junho de 2007. Arquivado do original (PDF) em 23 de outubro de 2008
- «ClozarilSide Effects & Drug Interactions». RxList. Consultado em 4 de junho de 2020. Arquivado do original em 4 de novembro de 2007
sites.google.com
- «Clozapine». Pharmacology: MCQs. Arquivado do original em 10 de novembro de 2013 – via Google Sites
uky.edu
uknowledge.uky.edu
- Li XB, Tang YL, Wang CY, de Leon J (maio de 2015). «Clozapine for treatment-resistant bipolar disorder: a systematic review». Bipolar Disorders. 17 (3): 235–247. PMID 25346322. doi:10.1111/bdi.12272
unc.edu
pdsp.unc.edu
- «PDSP Ki Database». Psychoactive Drug Screening Program (PDSP). University of North Carolina at Chapel Hill and the United States National Institute of Mental Health. Consultado em 14 de agosto de 2017 Verifique o valor de
|display-authors=Roth BL, Driscol J(ajuda) - «PDSP Ki Database». Psychoactive Drug Screening Program (PDSP). University of North Carolina at Chapel Hill and the United States National Institute of Mental Health. Consultado em 14 de agosto de 2017 Verifique o valor de
|display-authors=Roth BL, Driscol J(ajuda)
web.archive.org
- «Clozapine». The American Society of Health-System Pharmacists. Consultado em 1 de dezembro de 2015. Arquivado do original em 8 de dezembro de 2015
- «Supplemental NDA Approval Letter for Clozaril, NDA 19-758 / S-047» (PDF). United States Food and Drug Administration. 18 de dezembro de 2002. Consultado em 23 de novembro de 2012. Arquivado do original (PDF) em 8 de novembro de 2013
- «Letter to Novartis Pharmaceuticals Corporation» (PDF). Consultado em 20 de setembro de 2009. Arquivado do original (PDF) em 11 de maio de 2011
- Novartis Pharmaceuticals (abril de 2006). «Prescribing Information». Novartis Pharmaceuticals. 36 páginas. Consultado em 29 de junho de 2007. Arquivado do original (PDF) em 23 de outubro de 2008
- «Clozapine». Pharmacology: MCQs. Arquivado do original em 10 de novembro de 2013 – via Google Sites
- «A Guide for Patients and Caregivers: What You Need to Know About Clozapine and Neutropenia» (PDF). Clozapine REMS. Clozapine REMS Program. Consultado em 14 de setembro de 2021. Arquivado do original (PDF) em 22 de dezembro de 2017
- «Treatment of Clozapine-Induced Sialorrhea». Consultado em 8 de fevereiro de 2010. Arquivado do original em 9 de fevereiro de 2012
- «ClozarilSide Effects & Drug Interactions». RxList. Consultado em 4 de junho de 2020. Arquivado do original em 4 de novembro de 2007
- Robinson DS (2007). «CNS Receptor Partial Agonists: A New Approach to Drug Discovery». Primary Psychiatry. 14 (8): 22–24. Cópia arquivada em 18 de janeiro de 2012
- «Clozapine | C18H19ClN4». PubChem. U.S. Library of Medicine. Consultado em 16 de julho de 2017. Arquivado do original em 24 de dezembro de 2013
- «Clozapine International Brands». Drugs.com. Consultado em 28 de fevereiro de 2017. Arquivado do original em 1 de março de 2017
worldcat.org
- The clozapine handbook. [S.l.: s.n.] 16 de maio de 2019. ISBN 978-1-108-44746-1. OCLC 1222779588
- National Institute for Health and Care Excellence (Great Britain). Parkinson's disease in adults : diagnosis and management : full guideline. [S.l.: s.n.] OCLC 1105250833
- Taylor D, Shapland L, Laverick G, Bond J, Munro J (dezembro de 2000). «Clozapine – a survey of patient perceptions». Psychiatric Bulletin (em inglês). 24 (12): 450–452. ISSN 0955-6036. doi:10.1192/pb.24.12.450
- Thomson LD (julho de 2000). «Management of schizophrenia in conditions of high security». Advances in Psychiatric Treatment. 6 (4): 252–260. ISSN 1355-5146. doi:10.1192/apt.6.4.252
- Kasinathan J, Mastroianni T (dezembro de 2007). «Evaluating the use of enforced clozapine in an Australian forensic psychiatric setting: two cases». BMC Psychiatry. 7 (S1): P13. ISSN 1471-244X. PMC 3332745. doi:10.1186/1471-244x-7-s1-p13
- Swinton M, Haddock A (janeiro de 2000). «Clozapine in Special Hospital: a retrospective case-control study». The Journal of Forensic Psychiatry. 11 (3): 587–596. ISSN 0958-5184. doi:10.1080/09585180010006205
- «Schizophrenia, Violence, Clozapine and Risperidone: a Review». British Journal of Psychiatry. 169 (S31): 21–30. Dezembro de 1996. ISSN 0007-1250. doi:10.1192/s0007125000298589
- Swinton M (janeiro de 2001). «Clozapine in severe borderline personality disorder». The Journal of Forensic Psychiatry (em inglês). 12 (3): 580–591. ISSN 0958-5184. doi:10.1080/09585180110091994
- McLean G, Juckes L (1 de dezembro de 2001). «Parenteral Clozapine (Clozaril)». Australasian Psychiatry (em inglês). 9 (4). 371 páginas. ISSN 1039-8562. doi:10.1046/j.1440-1665.2001.0367a.x
- The Maudsley prescribing guidelines in psychiatry 13th ed. Hoboken, NJ: [s.n.] 2019. ISBN 978-1-119-44260-8. OCLC 1029071684
- Mistry H, Osborn D (julho de 2011). «Underuse of clozapine in treatment-resistant schizophrenia». Advances in Psychiatric Treatment. 17 (4): 250–255. ISSN 1355-5146. doi:10.1192/apt.bp.110.008128
- Downs J, Zinkler M (outubro de 2007). «Clozapine: national review of postcode prescribing». Psychiatric Bulletin (em inglês). 31 (10): 384–387. ISSN 0955-6036. doi:10.1192/pb.bp.106.013144
- Purcell H, Lewis S (novembro de 2000). «Postcode prescribing in psychiatry». Psychiatric Bulletin. 24 (11): 420–422. ISSN 0955-6036. doi:10.1192/pb.24.11.420
- Downs J, Zinkler M (outubro de 2007). «Clozapine: national review of postcode prescribing». Psychiatric Bulletin. 31 (10): 384–387. ISSN 0955-6036. doi:10.1192/pb.bp.106.013144